


A microscopic image of several cells, likely cancer cells, with prominent nuclei and complex, branching cytoplasmic structures. The cells are stained in shades of blue and purple, set against a dark background.

Annual Report 2025

eatris

European infrastructure
for translational medicine



Cytotoxic T-cells checking out Cancer cells
- Sci-Illustrate

With thanks to our funders and partners

 REPUBLIC OF BULGARIA Ministry of Education and Science	 REPUBLIC OF CROATIA Ministry of Science, Education and Youth	 MINISTRY OF EDUCATION, YOUTH AND SPORTS
REPUBLIC OF BULGARIA Ministry of Education and Science	REPUBLIC OF CROATIA Ministry of Science, Education and Youth	CZECH REPUBLIC Ministry of Education, Youth and Sports
 Research Council of Finland	 cea	 ISTITUTO SUPERIORE DI SANITÀ
REPUBLIC OF FINLAND Research Council of Finland	FRENCH REPUBLIC Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA)	ITALIAN REPUBLIC Istituto Superiore di Sanità (ISS)
 RĪGAS STRADIŅA UNIVERSITĀTE	 LE GOUVERNEMENT DU GRAND-DUCHÉ DE LUXEMBOURG	 ZonMw
REPUBLIC OF LATVIA Ministry of Education and Science	GRAND DUCHY OF LUXEMBOURG Le Gouvernement du Grand-Duché de Luxembourg	KINGDOM OF THE NETHERLANDS ZonMW
 The Research Council of Norway	 UNIVERSITETET I OSLO	 Infarmed Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.
KINGDOM OF NORWAY Research Council of Norway*	KINGDOM OF NORWAY University of Oslo*	REPUBLIC OF PORTUGAL INFARMED-National Authority of Medicines and Health Products
 REPUBLIC OF SLOVENIA MINISTRY OF HIGHER EDUCATION, SCIENCE AND INNOVATION	 ISCIII Instituto de Salud Carlos III	 Swedish Research Council
REPUBLIC OF SLOVENIA Ministry of Higher Education, Science and Innovation	KINGDOM OF SPAIN Instituto de Salud 'Carlos III' (ISCIII)	KINGDOM OF SWEDEN Vetenskapsrådet**
 VINNOVA		
KINGDOM OF SWEDEN Vinnova**		

*The contribution from Norway is from the University of Oslo
**The Swedish contribution is from Vinnova

contents

7

foreword

8 Joint Foreword from
EATRIS Boards

10

highlights

10 Timeline of Key Moments in 2025
12 2025 in Numbers

14

infrastructure

15 Map of Participating
Countries and Institutes
16 Infrastructure Overview
18 Updates from Member States
38 Impact
40 EATRIS Spotlight Programme
42 Institutions Overview

49

scientific updates

50 Message From EATRIS
Scientific Advisory Board
52 Platform Updates
58 Featured Publications
69 Digital Transformation
70 Repurposing at EATRIS

73

projects

74 Overview of Projects
76 Spotlight on Newly Launched
Projects in 2025
78 ISIDORe: From Crisis
to Preparedness

81

services and activities

82 Innovation Management and
Business Development
84 Spotlight on Mentoring
86 Advocacy and Partnerships
90 Patients Engagement Actions
92 Communications
94 Education and Training

99

financial summary

102

meet the community

106

abbreviations

foreword

Joint Foreword from EATRIS Boards



Jelena Ilić-Dreven
Chair of Board
of Governors



Claudia Faria
Chair of Board of
National Directors



Anton Ussi
Operations &
Finance Director



Toni Andreu
Scientific Director



Florence Bietrix
Deputy Director to
the Executive Board

Dear Reader,

2025 has been a year of consolidation, growth and ambition for EATRIS as Europe's research infrastructure for translational medicine.

We have strengthened our role as a trusted partner across the translational pathway - from early discovery to clinical application - reflected in 28 proposals submitted to the European Commission with EATRIS as a partner, while ensuring that our activities remain firmly grounded in patient benefit and societal impact.

A defining milestone this year was the continued implementation of our Impact Assessment Framework across the national nodes. Moving from design to delivery, we are now embedding the six Impact Pathways throughout the distributed infrastructure. This enables us to demonstrate more clearly how EATRIS contributes to research excellence, innovation, policy development and economic value - while remaining aligned with national priorities.

Our distributed model has also grown stronger. The Slovak Republic joined EATRIS as our 15th Member State, reflecting the continued relevance of a coordinated European approach to translational research. Across the infrastructure, institutions expanded their engagement in European projects, training activities and collaborative services, reinforcing EATRIS as a connector of expertise.

Digital transformation remains central to our strategy. Through EATRIS-CONNECT and related initiatives, we are advancing AI-driven tools, data integration and



digital health applications - from biomarkers and imaging to advanced therapies. New working groups, including Digital Biomarkers and AI in healthcare, reflect the evolving needs of the research and clinical communities.

Mentoring and capacity building continue to underpin our mission. Through REMEDi4ALL, RealiseD and other initiatives, we have supported researchers navigating regulatory, clinical and innovation pathways. Education and training activities have expanded further, strengthening Europe's translational workforce.

The EATRIS Spotlight Programme has matured into a strategic instrument for showcasing national excellence and fostering cross-border collaboration. By linking national strengths to European priorities, it demonstrates the value of a coordinated infrastructure.

We thank our members, partners and community for their continued commitment. Together, we are ensuring that scientific excellence translates into tangible improvements in health and well-being across Europe.

Jelena Ilić-Dreven, Chair of Board of Governors

Claudia Faria, Chair of Board of National Directors

Anton Ussi, Operations & Finance Director

Toni Andreu, Scientific Director

Florence Bietrix, Deputy Director to the Executive Board

highlights

Key moments in 2025



2025 in numbers

122

Citations in
Scientific Papers

28

Proposals Submitted
with EATRIS as Partner

36%

of Grant Proposals
Positively Reviewed

440

Scientific Platform
Members

98

Expert Advice and Mentoring
Sessions Performed

01

Public-Private Partnership
Hub with a Pharma Company

11

Research Service
Requests Handled

171

Institutions of Which
Over Half Are Medical

16

Service Requests from
Biotech Companies

OVERVIEW OF FUNDING GRANTED IN 2025


€3.3M**€177,300**

Research Services

€3.2M

Competitive Grants

EATRIS USERS



- Academia
- Patients/Carers
- Charities/Funders
- Large Pharma/Biotech
- SMES

EATRIS ONLINE

**651 hrs**

Total Watch Time
on YouTube

4.82M

Google Search Impressions

**65,450**

Website
Page Views

SOCIAL MEDIA

**7,069**

LinkedIn Followers

**624**

YouTube Followers

**305**

Facebook Followers

PARTICIPATION IN EATRIS EVENTS

33

Training Events
and Activities

312

Attendees at the
iDR25 International
Drug Repurposing
Conference


71

Speakers at the
International
Drug Repurposing
Conference

1,697

Attendees at
Training Events
and Activities

infrastructure in 2025




Map of Participating Countries and Institutes

Participating countries: Bulgaria, Croatia, Czech Republic, Finland, France, Italy, Latvia, Luxembourg, the Netherlands, Norway, Portugal, Slovenia, Spain and Sweden.




151 academic and non-profit research institutes of excellence; more than half are university medical centres.




Infrastructure Overview



updates from member states



Slovak Republic Becomes Member State of EATRIS-ERIC



The Slovak Republic officially joined EATRIS-ERIC in April 2025, becoming the 15th Member State of the infrastructure. Slovakia's entry into EATRIS-ERIC not only enhances the national research ecosystem but also adds new strengths and perspectives to the broader European translational research community.

Slovak delegation to EATRIS Board of Governors includes Ján Kočíšek and Simona Foltinová from Ministry of Education, Research, Development and Youth of the Slovak Republic and Erika Halašová, as scientific delegate and national director from Jessenius Faculty of Medicine in Martin, Comenius University Bratislava. Completing the Slovak delegation is Ján Strnádel, appointed as national coordinator.

The EATRIS community welcomes the Slovak Republic and looks forward to working closely together in the years ahead.

On behalf of the Board of Governors, Chair Jelena Ilić-Dreven commented:

“ We are pleased to welcome the Slovak Republic as the 15th member of EATRIS-ERIC. Their accession reflects a strong commitment to advancing translational research in Europe and adds valuable momentum to our collective mission. We look forward to a productive and inspiring collaboration with our new colleagues from Slovakia.”

Mr. Ján Kočíšek, Delegate of the Slovak Republic to the EATRIS Board of Governors, shared his perspective:

“ Joining EATRIS as a full member is a proud achievement for Slovakia and a testament to our ongoing investment in research and innovation. This membership aligns with Slovakia's strategic objectives in fostering cutting-edge biomedical research and personalised medicine. We are excited about the opportunities this membership opens for our institutions and researchers, and we are committed to contributing actively to the EATRIS community.”

Joining EATRIS underscores growing the commitment of the Slovak Republic to advancing research infrastructure and innovation in translational medicine.



Bulgaria

In 2025, government funding supported further investment in research infrastructure across EATRIS-affiliated institutions. This enabled the development of advanced experimental and development capabilities in cell biology, omics, and cell biotechnologies, supporting translational and personalised medicine.

The EATRIS-Bulgaria Annual Meeting was held in November, bringing together government representatives, ESFRI nodes, universities, and public and private stakeholders. The programme included the international symposium “Biomarkers in Translational Medicine - common goals and shared expertise” and a dedicated Youth Scientific Session, both of which attracted strong interest. The event was organised in partnership with the Health and Life Science Cluster Bulgaria, Artificial Intelligence Cluster, Sofia Tech Park, and IBM Bulgaria. Discussions focused on collaboration between researchers, AI developers, and industry, as well as the potential of integrated European health data platforms and the role of Bulgarian HPC centres in healthcare.

Overall, national engagement with EATRIS activities increased in 2025, supported by funding from the Ministry of Education and Science through INFRAACT.



**BOARD OF GOVERNORS
REPRESENTATIVE**

Yanita Zherkova



**NATIONAL
DIRECTOR**

Rossitza Konakchieva



**NATIONAL
COORDINATOR**

Georgi Georgiev



EATRIS Bulgaria took part in 3 education and training activities in 2025 involving 5 participants.

EATRIS Bulgaria was involved in the following ongoing projects in 2025:

- EATRIS-CONNECT
- ERDERA

EATRIS in Bulgaria consists of 3 institutes:

- Institute of Biology and Immunology of Reproduction, Bulgarian Academy of Sciences (IBIR-BAS)
- National Center of Infectious and Parasitic Diseases (NCIPD)
- Sofia University




Croatia

In 2025, the Croatian EATRIS node remained active in European collaboration and capacity building, with a focus on project development and training. UZSM continued its participation in the Horizon Europe project EATRIS-CONNECT. Several project proposals were prepared, including Erasmus+ applications such as Oncolight (coordinated by UZSM) and TRAC. Although positively evaluated, these were not funded and will be resubmitted. A Horizon Europe proposal for the ORBIT project was also submitted but not funded.

The node engaged with the wider EATRIS ecosystem to support research development. In collaboration with the University of Zagreb, discussions with REMEDI4ALL explored the development of a vaccine candidate, providing guidance for future work.

Training remained a priority, with doctoral students participating in the EATRIS “Translational Medicine Explained” course. Croatian institutions also contributed to European networking through the funded COST Action INFLAMomx. These activities reflect continued efforts to strengthen expertise, partnerships, and future opportunities.



**BOARD OF GOVERNORS
REPRESENTATIVE**

Jelena Ilić-Dreven



**NATIONAL
DIRECTOR**

Fran Borovečki



**NATIONAL
COORDINATOR**

Lozika Mašić



EATRIS Croatia took part in 5 education and training activities in 2025 involving 11 participants.

EATRIS Croatia was involved in the following ongoing projects in 2025:

- EATRIS-CONNECT

EATRIS in Croatia consists of 6 institutes:

- Faculty of Medicine Osijek, University Josip Juraj Strossmayer Osijek (MEFOS)
- Ruder Boskovic Institute (IRB)
- University of Rijeka Faculty of Medicine (MEDRI)
- University of Split School Medicine (USSM)
- University of Zagreb, Faculty of Pharmacy and Biochemistry (FPB)
- University of Zagreb, School of Medicine (UZSM)



Czech Republic

In 2025, EATRIS-CZ strengthened its role by delivering coordinated translational research services across key domains, including biomarkers, small molecules, imaging, vaccines and immunotherapy, and advanced therapeutics. The node continued to develop as an integrated infrastructure supporting the full translational pipeline.

Key priorities included service quality, interoperability, reproducibility, and alignment with EATRIS strategy and European research priorities. A major achievement was the development of a digital backbone for sensitive biomedical data and FAIR-compliant reuse.

Building on the IMTM Digital Hub and Trusted Research Environment, EATRIS-CZ aligned with the EOSC-CZ roadmap through the development of ClinData, a national controlled-access repository for human data. This was complemented by the LifeData portal and improved integration of laboratory and clinical workflows.

The node also strengthened its role in multi-omics and data-driven research through initiatives such as CzechGenome, supporting national coordination and alignment with European infrastructures including ELIXIR and the emerging EHDS.

Strong engagement was maintained through national events and international participation. Overall, EATRIS-CZ demonstrated clear progress in strengthening translational pipelines, digital infrastructure, and its international position within EATRIS.



BOARD OF GOVERNORS REPRESENTATIVE

Judita Klosakova



NATIONAL DIRECTOR

Marian Hajdúch



NATIONAL COORDINATOR

Erik Dvorak



EATRIS Czech Republic took part in 7 education and training activities in 2025 involving 15 participants.

EATRIS Czech Republic was involved in the following ongoing projects in 2025:

- EATRIS-CONNECT
- EOSC4-Cancer
- ERDERA
- CANDLE
- canSERV

EATRIS Czech Republic was involved in the following positively reviewed proposals in 2025:

- SIRENE
- STARDAST
- ISIDORE II

EATRIS in Czech Republic consists of 12 institutes:

- Central European Institute of Technologies (CEITEC)
- Charles University
- Institute of Chemical Technologies Prague
- Institute of Experimental Medicine AS CR

- Institute of Hematology and Blood Transfusion (IHBT)
- Institute of Macromolecular Chemistry Prague (IMC ASCR)
- Institute of microbiology of the AS CR, v.v.i
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences
- Masaryk University
- Nuclear Physics Institute of the ASCR/UJF, v. v. i.
- Palacky University - Institute of Molecular and Translational Medicine (IMTM)
- St. Anne's University Hospital Brno



Finland

In 2025, EATRIS-Finland focused on ATMP materials, including viral vectors, advanced immunological methods, PET imaging with novel ligands, and GMP manufacturing alongside preclinical GLP safety and efficacy studies.

A major effort was dedicated to the NordForsk ATMP Nordic hub application and the EATRIS Nordic webinar series, organised with Sweden and Norway.

A new tracer was added to the EATRIS tracer factory by the Turku PET Centre, and an EU Tracer Factory workshop was held during the Turku PET Symposium 2025.



BOARD OF GOVERNORS REPRESENTATIVE

Sirpa Nuotio



BOARD OF GOVERNORS REPRESENTATIVE

Jussi Pihlajamäki



NATIONAL DIRECTOR

Seppo Ylä-Herttuala



NATIONAL COORDINATOR

Petri Mäkinen



EATRIS Finland took part in 6 education and training activities in 2025 involving 16 participants.

EATRIS Finland was involved in the following ongoing projects in 2025:

- EATRIS-CONNECT
- ISIDORE
- ERDERA
- IRISE
- REMEDI4ALL
- RITIFI

EATRIS Finland was involved in the following positively reviewed proposals in 2025:

- SIRENE
- ISIDORE II
- STARDAST

EATRIS in Finland consists of 8 institutes:

- University of Turku Central Animal Laboratory (UTUCAL)
- Finnish Red Cross Blood Service
- Institute for Molecular Medicine Finland (FIMM)
- University of Tampere Regea Cell and Tissue Center



France

In 2025, the NeurATRIS infrastructure completed its Programme des Investissements d'Avenir phase and secured continued operations through annual state funding, ensuring long-term sustainability.

Technological capabilities were strengthened through the deployment of France 2030-funded equipment, including PET-TDM scanners, spatial transcriptomics and proteomics platforms, and high-resolution imaging systems, with further installations planned for 2026.

The infrastructure expanded its service offering by deploying digital solutions in France and the UK to monitor symptoms in patients with Huntington's and Parkinson's diseases. A new non-human primate model of Parkinson's disease was also validated, with strong potential for industrial collaboration.

NeurATRIS further developed industrial partnerships and co-organised Pasrel Imagerie Spring 2025. Scientific output remained strong, with 132 publications.

Within EATRIS, the French node contributed to the EU Tracer Factory initiative, including a workshop at the Turku PET Symposium, a presentation at BrainPET in Seoul, and submission of a COST Action on training, harmonisation, AI integration, and sustainable radiochemistry.



BOARD OF GOVERNORS REPRESENTATIVE

Catherine Le Chalony



NATIONAL DIRECTOR

Philippe Hantraye



NATIONAL COORDINATOR

Emilie Hangen



EATRIS France took part in 9 education and training activities in 2025 involving 40 participants.

EATRIS France was involved in the following ongoing projects in 2025:


- EATRIS-CONNECT
- ERDERA
- ISIDORE
- RealiseD
- RITIFI
- CANDLE

EATRIS France was involved in the following funding proposals in 2025:

- SIRENE
- STARDAST
- ISIDORE II

EATRIS in France consists of 5 institutes:

- CEA Paris-Saclay – MIRCen
- GHU Pitié-Salpêtrière – Paris Brain Institute
- Bicêtre Hospital – Neuro-Bicêtre
- Henri Mondor Hospital
- Oniris Nantes – UMR 703 PanTher
- Robert Debré Hospital – NeuroDiderot



Italy

In 2025, Italy continued to achieve strong results within EATRIS, with A_IATRIS focusing on participation in European, national, and regional projects, as well as strengthening access to private funding.

In training, a joint event was organised with other Italian research infrastructures, including ELIXIR-Italy and EBRAINS Italy. Following the 2024 course on "The Role of Artificial Intelligence in Diagnostic Imaging", a second edition was held in Rome in October 2025, focusing on advances in AI for imaging and its role in diagnosis and therapeutic follow-up.

ISS and A_IATRIS also organised the ADVANCE Course on Cellular and Gene Therapies 2025, held in February. Building on the Erasmus+ ADVANCE project, the course was updated and expanded in scope.

Italy continued its active participation in EATRIS projects, including EATRIS-CONNECT, REMEDI4ALL, UMBRELLA, and EDITSCD.



BOARD OF GOVERNORS REPRESENTATIVE

Francesca Capone



NATIONAL DIRECTOR

Franca Moretti



NATIONAL COORDINATOR

Chiara De Nuccio



EATRIS Italy took part in 11 education and training activities in 2025 involving 70 participants.

EATRIS Italy was involved in the following ongoing projects in 2025:

- EATRIS-CONNECT
- EUCAIM
- EDITSCD
- ERDERA
- ISIDORE
- CANDLE
- CanServ
- COMPASS-AI
- RealiseD
- REMEDI4ALL
- SIMPATHIC
- TRUSTroke
- UMBRELLA

EATRIS Italy was involved in the following positively reviewed proposals in 2025:

- SIRENE
- STARDAST
- ISIDORE II

EATRIS in Italy consists of the following institutes:

- Centro Regionale Specializzato per i Biomarcatori Diagnostici Prognostici e Predittivi, Azienda ULSS 3, Serenissima, Venezia
- Centro di Medicina Rigenerativa "Stefano Ferrari", Modena
- Centro di Riferimento Oncologico di Aviano IRCCS, Pordenone
- Consorzio Collezioe Nazionale dei Composti Chimici e Centro Screening, Roma

- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Fondazione Santa Lucia IRCCS, Roma
- SYNLAB SDN IRCCS, Napoli
- IFO, Istituto Nazionale Tumori Regina Elena IRCCS, Roma
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano
- Istituto "Giannina Gaslini" IRCCS, Genova
- Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione IRCCS, Palermo
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Napoli
- Istituto Oncologico Veneto IRCCS, Padova
- Istituto Ortopedico Galeazzi IRCCS, Milano
- Istituto Ortopedico Rizzoli IRCCS, Bologna
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, S.r.l. Meldola, Forlì-Cesena
- Istituto Superiore di Sanità, Roma (Coordinator)
- Ospedale Pediatrico Bambino Gesù IRCCS, Roma
- Ospedale San Raffaele IRCCS, Milano
- Università Cattolica del Sacro Cuore, Roma
- Università degli Studi di Milano-Bicocca



Latvia

In 2025, the Latvian EATRIS node, coordinated by Rīga Stradiņš University (RSU), strengthened both national and European research capacities.

A key focus was the Horizon Europe project EATRIS-CONNECT, where RSU leads activities on patient engagement. RSU also launched the national partnership project "Participation of RSU in the Horizon Europe Programme" (2025–2029), providing a framework for national coordination.

The node expanded from four to six institutions with the addition of BKUS and PSKUS, strengthening clinical research capacity.

RSU organised an EATRIS session at the PMNET Forum in collaboration with Norway and submitted a Horizon Europe proposal under HORIZON-HLTH-2025-03-IND-03. Communication and dissemination activities were carried out throughout the year.



BOARD OF GOVERNORS REPRESENTATIVE

Uldis Berkis



NATIONAL DIRECTOR

Liene Nikitina-Zake



NATIONAL COORDINATOR

Zaiga Nora-Krukle



EATRIS France took part in **9** education and training activities in 2025 involving **37** participants.

EATRIS Latvia was involved in the following ongoing projects in 2025:


- EATRIS-CONNECT
- ERDERA
- ISIDORE

EATRIS Latvia was involved in the following positively reviewed proposal in 2025:

- ISIDORE II

EATRIS in Latvia consists of **4** institutes:

- Latvian Biomedical Research and Study Centre (BMC)
- Latvian Institute of Organic Synthesis
- Riga Stradiņš University
- University of Latvia



Luxembourg

In 2025, the Luxembourg node continued to place patients and public value at the centre of translational research.

A key milestone was the transition of Clinnova into Phase 2, advancing the development of a Centre of Excellence in Digital Health and Personalised Healthcare. The creation of the Luxembourg Research Clinic further strengthened the national ecosystem by connecting clinicians, researchers, and stakeholders.

ISO 20387 accreditation of LIH and IBBL reinforced a strong quality and reproducibility framework. The Luxembourg Research Clinic hosted its first international conference, supported by EATRIS-Connect.

The node expanded industrial engagement and strengthened Patient and Public Involvement across projects. Participation in EATRIS-Connect supported alignment with national priorities and reinforced Luxembourg's position in translational research.



BOARD OF GOVERNORS REPRESENTATIVE

Jean-Claude Milmeister



NATIONAL DIRECTOR

Frank Glod



NATIONAL COORDINATOR

Catherine Nannan



EATRIS Luxembourg took part in **4** education and training activities in 2025 involving **8** participants.

EATRIS Luxembourg was involved in the following ongoing projects in 2025:

- EATRIS-CONNECT
- ERDERA
- CANDLE

EATRIS Luxembourg was involved in the following positively reviewed proposal in 2025:

- SIRENE

EATRIS in Luxembourg consists of **3** institutes:

- Integrated Biobank of Luxembourg (IBBL)
- Luxembourg Institute of Health (LIH)
- Luxembourg Center for System Biomedicine (LCSB)



The Netherlands

In 2025, the Dutch node, coordinated by Health-RI in close collaboration with FAST, continued to strengthen the national ecosystem for therapy development, with a focus on impact, collaboration, and societal value.

A key priority was the continued development of the CANDLE project, bringing together six ESFRIs and over 40 partners to establish national oncology data nodes across Europe. At the national level, Health-RI advanced regional and domain-specific data nodes in oncology and cardiovascular medicine, in collaboration with HMF, IKNL, and KWF. The emergence of a rare diseases domain node marked a further step in expanding the national data infrastructure.

By coordinating the Dutch nodes of EATRIS, BBMRI, and ELIXIR, Health-RI supported alignment between national and European research agendas and strengthened cross-ESFRI collaboration. This was complemented by regular interaction between Dutch EATRIS platform chairs to improve coordination and align activities.

TNO took on the role of chair of the newly established Digital Biomarker Working Group within the EATRIS Biomarker Platform, contributing to knowledge exchange and new collaborative initiatives with European partners.

EATRIS-NL also contributed to the EATRIS Training Platform and summer schools, and aligned with wider European developments, including EHDS and AI PERMED.

Looking ahead, Health-RI and FAST will continue to jointly strengthen EATRIS-NL, supporting national collaboration and accelerating therapy development.



**BOARD OF GOVERNORS
REPRESENTATIVE**

Ana de Castro



**NATIONAL
DIRECTOR**

Alain Van Gool



**NATIONAL
DIRECTOR**

Saco de Visser



**NATIONAL
COORDINATOR**

Andrea Mendez



EATRIS Netherlands took part in 11 education and training activities in 2025 involving 192 participants.

EATRIS Netherlands was involved in the following ongoing projects in 2025:

- EATRIS-CONNECT
- ERDERA
- EUCAIM
- CANDLE
- COMPASS-AiRISE
- iRISE
- ISIDORE
- EOSC4Cancer
- REMEDi4ALL
- RealiseD
- UMBRELLA
- RITIF

EATRIS Netherlands was involved in the following positively reviewed proposals in 2025:

- SIRENE
- STARDAST
- EASI-OMICS
- ISIDORE II

EATRIS in the Netherlands consists of 15 institutes:

- Amsterdam UMC - Academic Medical Centre (AMC)
- Amsterdam UMC - VU Medical Center (Vumc)

- Biomedical Primate Research Centre (BPRC)
- Erasmus University Medical Centre
- Intravacc
- Leiden University Medical Centre (LUMC)
- Maastricht University Medical Center (MUMC)
- Netherlands Cancer Institute
- Spinoza Centre for Neuroimaging
- TNO
- University Medical Center St Radboud (UMCN)
- University Medical Center Utrecht (UMCU)
- University Medical Centre Groningen (UMCG)
- University of Technology Eindhoven (TU/e)
- Wageningen Bioveterinary Research



Norway

In 2025, the Norwegian node focused on strengthening national and Nordic collaboration, increasing visibility of EATRIS services, and supporting translational research.

A national node meeting brought together EBRAINS, ELIXIR, Biobank OUS, NorCRIN, and AI stakeholders. At the Nordic level, the node co-organised an ATMP webinar series with Finland and Sweden, with participation from Denmark.

EATRIS matchmaking services contributed to a successful national funding application. A UiO:Life Science proposal was also prepared, focusing on matchmaking and mapping research capacity.

Outreach activities included presentations, patient engagement events, and participation in international forums. The node also engaged with the Norwegian innovation ecosystem.



**BOARD OF GOVERNORS
REPRESENTATIVE**

Olja Toljagic




**NATIONAL
DIRECTOR**

Janna Saarela



**NATIONAL
COORDINATOR**

Anita Kavlie



EATRIS Norway took part in 8 education and training activities in 2025 involving 21 participants.

EATRIS Norway was involved in the following ongoing projects in 2025:

- EATRIS-CONNECT
- EOSC4Cancer
- ERDERA
- ISIDORE
- CanServ
- RealiseD
- CANDLE

EATRIS Norway was involved in the following positively reviewed proposals in 2025:

- SIRENE
- ISIDORE II

EATRIS in Norway consists of 5 institutes:

- Norwegian Medical Cyclotroncentre AS
- Norwegian University of Science and Technology (NTNU)
- University of Bergen (UiB) and Haukeland University Hospital
- University of Oslo (UiO) and Oslo

**Norway is no longer a member as of 2026.*





Portugal

In 2025, the Portuguese node strengthened its role by combining the national Spotlight Programme with EATRIS-CONNECT activities, supporting the translation of research into clinical application.

The Spotlight Programme delivered eight cross-institutional events with international experts. A joint closing event highlighted key outcomes and reinforced collaboration.

Efforts focused on improving translation through multi-omics approaches and advanced models such as 3D organoids, strengthening regulatory pathways with INFARMED, and promoting patient involvement, including in decentralised clinical trials.

EATRIS-CONNECT supported the development of a digital expert network and the use of digital tools in clinical decision-making. INFARMED contributed to aligning research with policy frameworks and supporting digital transformation in personalised medicine.



BOARD OF GOVERNORS REPRESENTATIVE

Rui Santos Ivo



NATIONAL DIRECTOR

Claudia Faria



NATIONAL COORDINATOR

Helena Baião



EATRIS Portugal took part in 9 education and training activities in 2025 involving 57 participants.

EATRIS Portugal was involved in the following ongoing projects in 2025:

- EATRIS-CONNECT
- ERDERA
- COMPASS-AI
- CANDLE
- ISIDORE
- CanServ
- UMBRELLA
- RITIFI

EATRIS Portugal was involved in the following positively reviewed proposals in 2025:

- SIRENE
- ISIDORE II
- TransBioNet

EATRIS Portugal consists of the following institutes:

- 3B's Research Institute, University of Minho
- AccelBio
- Association for Innovation and Biomedical Research on Light and Image (AIBILI)

- Center for Neuroscience and Cell Biology, Coimbra University Hospital
- Chamalimaud Foundation
- Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT)
- Coimbra Institute for Clinical and Biomedical Research (ICBR)
- Institute for Bioengineering and Biosciences - Stem Cell Engineering Research Group (iBB - SCERG)
- Institute of Biomedicine (IBIMED)
- Instituto de Biologia Experimental e Tecnológica (IBET)
- Instituto de Investigação e Inovação em Saúde (i3S)
- Instituto de Medicina Molecular João Lobo Antunes (IMM)
- Instituto Pedro Nunes (IPN)
- Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto)
- Life and Health Sciences Research Institute / Clinical Academic Centre - Braga
- NOVA Medical School, Universidade NOVA de Lisboa (NMS, NOVA)
- RISE-Health
- University of Beira Interior, Health Sciences Research Center (CICS-UBI)
- VectorB2B




Slovakia

Following accession to EATRIS in May 2025, the Slovak node, coordinated by Jessenius Faculty of Medicine and the Biomedical Centre Martin, focused on consolidation and alignment with the EATRIS mission.

Activities centred on strengthening national coordination, mapping competencies to EATRIS services, and preparing for deeper engagement within the European ecosystem.

In this initial phase, the node prioritised capacity building and alignment with EATRIS standards rather than high-volume service provision, laying the groundwork for future participation.



BOARD OF GOVERNORS REPRESENTATIVE

Ján Kočíšek




NATIONAL DIRECTOR

Erika Halašová



NATIONAL COORDINATOR

Ján Strnádel




EATRIS Slovakia took part in 6 education and training activities in 2025 involving 6 participants.

EATRIS Slovakia was involved in the following ongoing projects in 2025:

- ERDERA
- ISIDORE

EATRIS Slovakia was involved in the following positively reviewed proposal in 2025:

- ISIDORE II





Slovenia

In 2025, EATRIS Slovenia delivered activities across education, training, stakeholder engagement, and research.

The node organised two international ECTS-accredited summer schools and continued an online ATMP course, training over 100 participants. Stakeholder engagement included major events such as the REMEDI4ALL General Assembly and UNI.MINDS Biotechnology Summit.

The node contributed eight scientific publications acknowledging EATRIS support and participated in three project applications.

These activities supported capacity building, collaboration, and the advancement of translational research at national and European levels.



BOARD OF GOVERNORS REPRESENTATIVE

Albin Kralj



NATIONAL DIRECTOR

Irena Mlinarič-Raščan



NATIONAL COORDINATOR

Dunja Urbančič



EATRIS Slovenia took part in 8 education and training activities in 2025 involving 55 participants.

EATRIS Slovenia was involved in the following ongoing projects in 2025:

- EATRIS-CONNECT
- ERDERA
- CANDLE
- REMEDI4ALL
- SIMPATHIC
- RITIFI

EATRIS Slovenia was involved in the following funding proposals in 2025:

- SIRENE
- ISIDORE II

EATRIS in Slovenia consists of 4 institutes:

- Centre for the Technologies of Gene and Cell Therapy, National Institute of Chemistry (CTGCT)
- Maribor University
- University of Ljubljana, Faculty of Pharmacy
- University Medical Centre Ljubljana (UMCL) Department of Nuclear Medicine



Spain

In 2025, the Spanish node strengthened its role within the European translational research ecosystem, enhancing national capacity and international collaboration.

Investments in advanced therapies, genomics, and research infrastructure improved technological capabilities and service provision. Strong engagement was seen from academia and industry.

Spain remained highly active in European and international funding programmes, including Horizon Europe, COST Actions, and EU-LAC collaborations.

A key highlight was the consolidation of the Spain in the Spotlight initiative on Climate Change and Health, culminating in a high-level international conference and strengthened patient engagement.

New initiatives also opened pathways for long-term collaboration with Latin America. Overall, Spain reinforced its position as a dynamic and internationally engaged EATRIS node.



BOARD OF GOVERNORS REPRESENTATIVE

Daniel Ruiz Iruela



NATIONAL DIRECTOR

Laura Garcia Bermejo



NATIONAL COORDINATOR

David Velasco Gail



EATRIS Spain took part in 12 education and training activities in 2025 involving 151 participants.

EATRIS Spain was involved in the following ongoing projects in 2025:

- EATRIS-CONNECT
- ERDERA
- EUCAIM
- CANDLE
- COMPASS-AI
- ISIDORE
- CanServ
- EOSC4Cancer
- SIMPATHIC
- REMEDI4ALL
- TRUSTroke
- RealiseD
- UMBRELLA

EATRIS Spain was involved in the following positively reviewed proposals in 2025:

- SIRENE
- EASI-OMICS
- ISIDORE II

EATRIS in Spain consists of 35 institutes:

- August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
- Bellvitge Biomedical Research Institute (IDIBELL)
- BioDonostia Health Research Institute
- FIBICO, Foundation for Biomedical Research of Cordoba (IMIBIC)
- Fundació Institut d'Investigació i Innovació Parc Taulí (I3PT)
- Fundación Instituto de Investigación Sanitaria de Navarra (IdiSNA)
- Fundación Jimenez Diaz Institute

for Medical Research (IIS-FJD)

- Galicia Sur Health Research Institute (IISGS)
- Germans Trias i Pujol Foundation (IGTP)
- Gregorio Marañon Health Research Institute (IISGM)
- Health Research Institute Biocruces Bizkaia
- Health Research Institute of the Balearic Islands (IdISBa)
- Health Research Institute of the Puerta de Hierro Majadahonda-Segovia de Arana (IDIPHISA)
- Health Research Institute of Santiago de Compostela (IDIS)
- Health Research Institute of Asturias (ISPA)
- Hospital Clínico San Carlos (IdISSC)
- Hospital de la Santa Creu i Sant Pau (IR-HSCSP)
- Hospital La Fe (IIS-La Fe)
- Hospital La Paz Institute for Health Research (IdiPAZ)
- INCLIVA
- Institute of Biomedical Research of A Coruña (INIBIC)
- Institute of Biomedicine of Seville (IBIS)
- Institut de Recerca Biomèdica de Lleida Fundació Dr. Pifartré (IRBLLEIDA)
- Institut Hospital Del Mar d'investigacions Mèdiques
- Instituto de Investigación Biomédica de Salamanca (IBSAL)
- Instituto de Investigación Biosanitaria (IBS GRANADA)
- Instituto de Investigación Marqués de Valdecilla (IDIVAL)
- Instituto de Investigación Sanitaria Aragón (IIS Aragón)
- Instituto Ramón ISIDORE Cajal (IRYCIS)
- Malaga Health Research Institute
- Research Institute Hospital Universitario 12 de Octubre (i+12 institute)
- University Hospital La Princesa (IIS-IP)
- Biomedical Research Institute of Murcia (IMIB)
- Vall d'Hebron Research Institute (VHIR)
- Valencian Community Foundation for the Management of the Health and Biomedical Research Institute of Alicante (ISABIAL)



Sweden

In 2025, the Swedish node focused on collaboration, visibility, and knowledge exchange. A key highlight was hosting the Spotlight Programme symposium on “AI in healthcare: opportunities, challenges and ethical considerations”, attracting strong participation from EATRIS nodes and national stakeholders.

Integration within SciLifeLab further strengthened collaboration and future synergies. An online workshop on AI in biomarker research also drew high interest.

EATRIS was promoted at major industry events and through outreach activities. A joint NordForsk ATMP application, although not funded, strengthened Nordic collaboration.

The Bridging Nordic ATMP webinar series continued with strong participation, including engagement from Denmark.



BOARD OF GOVERNORS REPRESENTATIVE

Helena Berglund



NATIONAL DIRECTOR

Pontus Aspenström



NATIONAL COORDINATOR

Ulrika Bäckman



EATRIS Sweden took part in 10 education and training activities in 2025 involving 31 participants.

EATRIS Sweden was involved in the following ongoing projects in 2025:



- EATRIS-CONNECT
- ERDERA
- EUCAIM
- CANDLE
- CanSERV
- REMEDI4ALL
- EOSC4Cancer
- ERIC-Forum 2
- RITIFI

EATRIS Sweden was involved in the following positively reviewed proposals in 2025:

- SIRENE
- EASI-OMICS
- ISIDORE II

EATRIS in Sweden consists of 15 institutes:

- Chalmers University of Technology
- Karolinska Institute
- KTH Royal Institute of Technology
- Linköping University
- Lund University



Impact Assessment

EATRIS advances translational medicine by ensuring that scientific discoveries are effectively translated into patient benefit and societal value. Our impact spans research, policy and society, and economy and innovation, reflecting EATRIS' role as Europe's research infrastructure for translational medicine.

Following the launch of the EATRIS Impact Assessment Framework and its six Impact Pathways in 2024, activities in 2025 focused on extending the framework across the EATRIS National Nodes. This marked a shift from framework development to implementation, ensuring that impact is captured consistently across the entire distributed infrastructure while remaining aligned with diverse national priorities and evaluation systems.

Under the Horizon Europe EATRIS-CONNECT project, dedicated Impact Working Groups at Coordination & Support and node level carried out a mapping exercise to align national reporting practices with the six Impact Pathways. The aim is to provide a flexible, node-adaptable framework that supports both EATRIS-wide impact reporting and national accountability to funders and policy-makers.

Two workshops held in Stockholm (May) and Lisbon (December) brought together National Directors, Coordinators, and Board of Governors representatives to validate the approach and agree on next steps.

From 2026 onwards, national nodes will complement the three core KPIs already collected through Annual Node Reports (namely the number of users, publications and person hours trained) by prioritising additional pathway-aligned indicators and contributing qualitative impact evidence. This work strengthens EATRIS' capacity to demonstrate the full value of a European research infrastructure - advancing science while delivering tangible benefits for innovation, policy, and society.

To capture this breadth of activity, EATRIS organises its work across six Impact Pathways:

SUPPORT SCIENCE POLICY


EATRIS works closely with funders, regulators and policy-makers to strengthen the environment for translational medicine in Europe. By providing expertise and evidence, we support informed decision-making and highlight the value of research infrastructures for improving human health.

9 policy statements and consultations, and 19 policy-focused workshops/events in 2025

ENABLE UPTAKE OF RESEARCH AND INNOVATION RESULTS

EATRIS helps promising discoveries move beyond the "valley of death" towards practical application. By connecting expertise, data and services across Europe, we accelerate the uptake of research results into sustainable solutions for patients and society.

Nearly 7,000 users accessed EATRIS open resources, with 148 publications involving or acknowledging EATRIS in 2025



From National Excellence to European Impact - The EATRIS Spotlight Programme

In 2025, the EATRIS Spotlight Programme matured into a strategic instrument for showcasing national excellence, strengthening node capacity and reinforcing EATRIS' distributed model for translational medicine. Launched in 2024, the programme provides each EATRIS member country with a structured six-month Spotlight period to highlight national research strengths, engage stakeholders, and align national priorities with EATRIS' strategic objectives. In close coordination with the EATRIS Coordination and Support Office, Spotlight countries benefit from enhanced visibility and targeted support to bring their excellence into European focus.



During 2025, Sweden concluded its Spotlight with a thematic focus on artificial intelligence in healthcare, including a high-level interdisciplinary symposium in Stockholm that connected research, innovation, and ethics communities. From May to December 2025, Portugal assumed the Spotlight under the theme "Bridging gaps in healthcare: developing solutions across the lifespan", mobilising its national node through eight hybrid events, dedicated working groups and patient-focused initiatives, and concluding with a final event in Lisbon.

An important milestone in 2025 was the Spotlight Roundtable held in Lisbon, which brought together National Directors from past, present and future Spotlight countries to reflect on implementation experiences and future possibilities. Coinciding with the roundtable, the Spotlight Programme Terms of Reference were released, providing a transparent, structured framework for future Spotlight cycles and ensuring consistency, fairness, and long-term sustainability.

The Spotlight Programme has proven effective in increasing the visibility of national nodes, stimulating collaboration, and strengthening engagement with national funders and stakeholders. Looking ahead, the programme will continue with the Czech Republic, followed by Italy, and Latvia, reflecting strong community uptake and long-term strategic relevance.

COUNTRIES IN THE SPOTLIGHT



ENGAGEMENT IN NUMBERS

13
EATRIS Meets
profiles published

22
Events organised (in
person & hybrid)

1,329
Attendees at events

14
Engagements with
other EATRIS nodes

08
Engagements with
external stakeholders

KEY OUTCOMES

Mobilising the national community around a strategically relevant scientific topic

Increased node visibility, recognition of expertise and positioning within the EATRIS infrastructure

Enabling new collaboration opportunities

Demonstrating sustained commitment and added value to national funders

Broader engagement in external thematic events, strengthening stakeholder relationships and EATRIS' European presence

Strengthened communication and outreach through events, digital channels, and dissemination of institutional expertise

Institutions Overview

- Platform participation in 2025
- New institutions in 2025

Name	ATMP	Biomarkers	Imaging & Tracing	Small Molecules	Vaccines
BULGARIA					
Institute of Biology and Immunology of Reproduction, Bulgarian Academy of Sciences (IBIR-BAS)					
National Center of Infectious and Parasitic Diseases (NCIPD)					
Sofia University					
CROATIA					
Faculty of Medicine Osijek, University Josip Juraj Strossmayer Osijek (MEFOS)					
Ruder Boskovic Institute (IRB)					
University of Rijeka Faculty of Medicine (MEDRI)					
University of Split School Medicine (USSM)					
University of Zagreb, Faculty of Pharmacy and Biochemistry (FPB)					
University of Zagreb, School of Medicine (UZSM)					
CZECH REPUBLIC					
Central European Institute of Technologies (CEITEC)					
Charles University					
Institute of Chemical Technologies Prague					
Institute of Experimental Medicine AS CR					
Institute of Hematology and Blood Transfusion (IHBT)					
Institute of Macromolecular Chemistry Prague (IMC ASCR)					
Institute of microbiology of the AS CR, v.v.i					
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences					
Masaryk University					
Nuclear Physics Institute of the ASCR/UJF, v. v. i.					
Palacky University - Institute of Molecular and Translational Medicine (IMTM)					
St. Anne's University Hospital Brno					
FINLAND					
Finnish Red Cross Blood Service					
University of Eastern Finland - National Virus Vector Laboratory (NVVL)					
University of Helsinki - Institute for Molecular Medicine Finland (FIMM)					
University of Tampere - Regea Cell and Tissue Center					
University of Turku and Turku University Hospital					
VTT Technical Research Centre of Finland (VTT)					
FRANCE					
Neuratrís-Albert Chevalier-Henri Mondor Hospital					

- Platform participation in 2025
- New institutions in 2025

Name	ATMP	Biomarkers	Imaging & Tracing	Small Molecules	Vaccines
Neuratrís-Biotherapies Institute for Rare Diseases (BIRD)					
Neuratrís-Brain & Spine Institute IHU-A-ICM					
Neuratrís-French Alternative Energies and Atomic Energy Commission (CEA)					
Neuratrís-Neurosciences Bicêtre - Paris Sud (NBPS)					
ITALY					
Centro di Riferimento Oncologico di Aviano (CRO Aviano)					
Centro Medicina Rigenerativa (CMR)					
CNCCS - IRBM Science Park					
Fondazione IRCCS CRIBT					
Fondazione IRCCS Fondazione Pascale					
Fondazione IRCCS Giovanni Paolo II					
Fondazione IRCCS Istituto Nazionale dei Tumori (INT-Milan)					
Fondazione IRCCS Ospedale Pediatrico Bambino Gesù					
Fondazione IRCCS SDN per la Ricerca e l'Alta Formazione in Diagnostica Nucleare					
Fondazione Policlinico Universitario A. Gemelli IRCCS					
IDI-Fondazione IRCCS Luigi Maria Monti					
IRCCS Foundation Santa Lucia					
IRCCS Istituto Giannina Gaslini (IGG)					
IRCCS Istituto Ortopedico Galeazzi					
ISMETT					
Istituti Fisioterapici Ospitalieri - Istituto Dermatologico "San Gallicano"					
Istituti Fisioterapici Ospitalieri - Regina Elena Tumor research					
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - IRCCS					
Istituto Superiore di Sanità (ISS)					
Mario Negri Institute for Pharmacological Research					
National Institute for Infectious Diseases Lazzaro Spallanzani					
Rizzoli Orthopedic Institute (IOR)					
Scientific Institute San Raffaele (HSR)					
University Milano-Bicocca (UNIMIB)					
LATVIA					
Latvian Biomedical Research and Study Centre (BMC)					
Latvian Institute of Organic Synthesis (OSI)					
Riga Stradins University (RSU)					

- Platform participation in 2025
- New institutions in 2025

Name	ATMP	Biomarkers	Imaging & Tracing	Small Molecules	Vaccines
University of Latvia		●		●	
LUXEMBOURG					
Integrated Biobank of Luxembourg (IBBL)	●	●	●	●	●
Luxembourg Institute of Health (LIH)	●	●	●	●	●
Luxembourg Center of System Biomedicine (LCSB)	●	●	●	●	●
THE NETHERLANDS					
Amsterdam UMC - Academic Medical Centre (AMC)	●	●	●	●	●
Amsterdam UMC - VU Medical Center (Vumc)	●	●	●	●	●
Biomedical Primate Research Centre (BPRC)	●	●	●	●	●
Erasmus University Medical Centre	●	●	●	●	●
Intravacc	●	●	●	●	●
Leiden University Medical Centre (LUMC)	●	●	●	●	●
Maastricht University Medical Center (MUMC)	●	●	●	●	●
Netherlands Cancer Institute	●	●	●	●	●
Spinoza Centre for Neuroimaging	●	●	●	●	●
TNO	●	●	●	●	●
University Medical Center St Radboud (UMCN)	●	●	●	●	●
University Medical Center Utrecht (UMCU)	●	●	●	●	●
University Medical Centre Groningen (UMCG)	●	●	●	●	●
University of Technology Eindhoven (TU/e)	●	●	●	●	●
Wageningen Bioveterinary Research	●	●	●	●	●
NORWAY					
Norwegian Medical Cyclotroncenter AS	●	●	●	●	●
Norwegian University of Science and Technology (NTNU)	●	●	●	●	●
University of Bergen (UiB) and Haukeland University Hospital	●	●	●	●	●
University of Oslo (UiO) and Oslo University Hospital (OUH)	●	●	●	●	●
University of Tromsø (UiT) and University Hospital North Norway	●	●	●	●	●
PORTUGAL					
3B's Research Institute, University of Minho	●	●	●	●	●
AccelBio	●	●	●	●	●
Association for Innovation and Biomedical Research on Light and Image (AIBILI)	●	●	●	●	●
Center for Neuroscience and Cell Biology; Coimbra University Hospital	●	●	●	●	●
Champalimaud Foundation	●	●	●	●	●
Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT)	●	●	●	●	●
Coimbra Institute for Clinical and Biomedical Research (iCBR)	●	●	●	●	●
Institute for Bioengineering and Biosciences - Stem Cell Engineering Research Group (iBB - SCERG)	●	●	●	●	●

- Platform participation in 2025
- New institutions in 2025

Name	ATMP	Biomarkers	Imaging & Tracing	Small Molecules	Vaccines
Institute of Biomedicine (IBIMED)	●	●	●	●	●
Instituto de Biologia Experimental e Tecnológica (IBET)	●	●	●	●	●
Instituto de Investigacao e Inovacao em Saude (i3S)	●	●	●	●	●
Instituto de Medicina Molecular João Lobo Antunes (IMM)	●	●	●	●	●
Instituto Pedro Nunes (IPN)	●	●	●	●	●
Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto)	●	●	●	●	●
Life and Health Sciences Research Institute / Clinical Academic Centre - Braga	●	●	●	●	●
NOVA Medical School, Unicersidade NOVA de Lisboa (NMS, NOVA)	●	●	●	●	●
RISE-Health	●	●	●	●	●
VectorB2B	●	●	●	●	●
SLOVENIA					
Centre for the Technologies of Gene and Cell Therapy, National Institute of Chemistry (CTGCT)	●	●	●	●	●
Maribor University	●	●	●	●	●
University of Ljubljana	●	●	●	●	●
University Medical Center Ljubljana, Department of Nuclear Medicine	●	●	●	●	●
SPAIN					
August Pi i Sunyer Biomedical Research Institute (IDIBAPS)	●	●	●	●	●
Bellvitge Biomedical Research Institute (IDIBELL)	●	●	●	●	●
BioDonostia Health Research Institute	●	●	●	●	●
FIBICO, Foundation for Biomedical Research of Cordoba (IMIBIC)	●	●	●	●	●
Fundació Institut d'Investigació i Innovació Parc Taulí (I3PT)	●	●	●	●	●
Fundación Instituto de Investigacion Sanitaria de Navarra (IdISNA)	●	●	●	●	●
Fundación Jimenez Diaz Institute for Medical Research (IIS-FJD)	●	●	●	●	●
Galicia Sur Health Research Institute (IISGS)	●	●	●	●	●
Germans Trias i Pujol Foundation (IGTP)	●	●	●	●	●
Gregorio Maranon Health Research Institute (IiSGM)	●	●	●	●	●
Health Research Institute Biocruces Bizkaia	●	●	●	●	●
Health Research Institute of the Balearic Islands (IdISBa)	●	●	●	●	●
Health Research Institute of the Puerta de Hierro Majadahonda-Segovia de Arana (IDIPHISA)	●	●	●	●	●
Health Research Institute of Santiago de Compostela (IDIS)	●	●	●	●	●
Health Research Institute of Asturias (ISPA)	●	●	●	●	●
Hospital Clínico San Carlos (IdISSC)	●	●	●	●	●
Hospital de la Santa Creu i Sant Pau (IR-HSCSP)	●	●	●	●	●
Hospital La Fe (IIS-La Fe)	●	●	●	●	●
Hospital La Paz Institute for Health Research (IdiPAZ)	●	●	●	●	●
INCLIVA	●	●	●	●	●

- Platform participation in 2025
- New institutions in 2025


Name	ATMP	Biomarkers	Imaging & Tracing	Small Molecules	Vaccines
Institute of Biomedical Research of A Coruña (INIBIC)	●	●	●	●	●
Insitute of Biomedicine of Seville (IBIS)	●	●	●	●	●
Institut de Recerca Biomèdica de Lleida Fundació Dr. Pifarré (IRBLLEIDA)	●	●	●	●	●
Institut Hospital Del Mar D'investigacions Mèdiques (IMIM)	●	●	●	●	●
Instituto de Investigación Biomédica de Salamanca (IBSAL)	●	●	●	●	●
Instituto de Investigación Biosanitaria (IBS GRANADA)	●	●	●	●	●
Instituto de Investigación Marqués de Valdecilla (IDIVAL)	●	●	●	●	●
Instituto de Investigación Sanitaria Aragón (IISAragon)	●	●	●	●	●
Instituto Ramón y Cajal (IRYCIS)	●	●	●	●	●
Malaga Health Research Institute	●	●	●	●	●
Research Institute Hospital Universitario 12 de Octubre (+12 institute)	●	●	●	●	●
University Hospital La Princesa (IIS-IP)	●	●	●	●	●
Biomedical Research Institute of Murcia (IMIB)	●	●	●	●	●
Vall d'Hebron Research Institute (VHIR)	●	●	●	●	●
Valencian Community Foundation for the Management of the Health and Biomedical Research Institute of Alicante (ISABIAL)	●	●	●	●	●
SWEDEN					
Chalmers University of Technology	●	●	●	●	●
Swedish National Infrastructure for Biological Mass Spectrometry	●	●	●	●	●
Karolinska Institute	●	●	●	●	●
KTH Royal Institute of Technology	●	●	●	●	●
Linköping University	●	●	●	●	●
Lund University	●	●	●	●	●
Protein Production Sweden (PPS), University of Gothenburg	●	●	●	●	●
SciLifeLab	●	●	●	●	●
Stockholm University	●	●	●	●	●
Testa Center	●	●	●	●	●
Umeå University	●	●	●	●	●
University of Gothenburg	●	●	●	●	●
Uppsala University and Uppsala University Hospital	●	●	●	●	●

A fluorescence microscopy image showing a dense population of cells. The cells are stained with three different fluorescent dyes: a blue dye (likely DAPI) that highlights the nuclei, a green dye that appears to stain the cytoplasm or certain organelles, and a red dye that highlights specific structures, possibly mitochondria or lipid droplets. The overall image has a dark background, making the brightly stained cells stand out. The text 'scientific updates' is overlaid in the upper right quadrant in a white, sans-serif font.

scientific updates

Message from EATRIS Scientific Advisory Board

The EATRIS SAB is formed of external scientific experts that provide independent feedback and advice on the scientific strategy of the organisation.



Catherine Larue

Fatima Nunez

Håkan Billig

Hugo Van
Heuverswyn

Nicole Déglon*

Petr Kocis

*We would like to thank Nicole Déglon for her valued contribution to the EATRIS Scientific Advisory Board. Her expertise and insight have been greatly appreciated, and her engagement has helped shape the direction of EATRIS during an important phase of its development. We wish her all the very best in her future endeavours.

Dear Reader,

In 2025, EATRIS has continued to consolidate its role as Europe's research infrastructure for translational medicine, combining scientific excellence with growing strategic clarity. As the Scientific Advisory Board (SAB), we provide independent guidance to help ensure that EATRIS remains aligned with Member State priorities, responsive to emerging challenges, and focused on delivering meaningful impact.

2025 year reflects strong operational progress and disciplined execution. Increased activity in personalised medicine, solid performance in European projects, and greater selectivity in project engagement demonstrate a maturing organisation attentive to both scientific ambition and financial sustainability.

Digital transformation has advanced significantly. The move from concept to implementation - including AI-enabled use cases such as the pancreatic cancer pilot - marks an important step. The Board sees strong potential in positioning digital activities not only as services, but as strategic assets that generate insight and continuously strengthen the translational pipeline.

Looking ahead to the next strategic cycle, EATRIS has an opportunity to further anchor its roadmap in clearly identified unmet needs across the translational continuum, informed by Member States, researchers, clinicians, regulators, industry, funders and, in particular, patients. Such alignment will reinforce relevance and competitiveness at European level.

Impact remains central. Continued refinement of impact indicators - capturing patient benefit, regulatory progress, innovation outputs and economic value - will help articulate more clearly how EATRIS contributes to strengthening Europe's health and research ecosystem. Equally, a structured and differentiated approach to patient engagement will further enhance credibility and inclusiveness.

The SAB commends EATRIS for the progress achieved and encourages continued focus on strategic alignment, measurable impact and long-term sustainability as it prepares for the coming decade, especially as we approach the next strategic plan.

Catherine Larue (Founder of Consulting in Biotechnology and Diagnostic, CoDx)

Fatima Nunez (Hospital Sant Joan de Deu Barcelona)

Håkan Billig (Professor at Gothenburg University and Chair of the SciLife Lab Steering Board)

Hugo Van Heuverswyn (FlandersBio)

Nicole Déglon (Lausanne University Hospital, CHUV)

Petr Kocis (Alzheon Inc)

platform updates

Advanced Therapies Medicinal Products (ATMP)



CO-CHAIRS:

Giuliana Ferrari (IRCCS Ospedale San Raffaele, Italy)

Maria Themeli (Amsterdam UMC, the Netherlands)



PLATFORM MANAGER:

David Morrow (Scientific Lead Advanced Therapies, EATRIS)

In 2025, the EATRIS Advanced Therapy Medicinal Products (ATMP) Platform marked a year of growth, strategic leadership and strengthened European collaboration. The platform expanded to 56 institutions, welcoming three new centres: the Institute of Haematology and Blood Transfusion (IHBT, Czech Republic), RISE-Health (Portugal), and the Centre for the Technologies of Gene and Cell Therapy (CTGCT) at the National Institute of Chemistry (Slovenia). This expansion reinforced pan-European expertise across translational science, Good Manufacturing Practice (GMP), regulatory strategy and clinical development, consolidating EATRIS' role as a central connector within Europe's advanced therapy ecosystem.

A major highlight was EATRIS' leadership in the ATMP component of the PRECISEU project. With support from the EMA, EATRIS spearheaded a strategic initiative to map Europe's capabilities for developing and delivering ATMPs. This first pan-European sustainable process captures capacities across academic centres, GMP and pre-

GMP manufacturing facilities, clinical trial hubs and regulatory support structures, ensuring visibility not only of current capabilities but of future development. Beyond cataloguing infrastructure, the initiative supports smarter investment in under-resourced regions, accelerates regulatory approvals and trial deployment, promotes cross-border collaboration and standardisation, and strengthens synergies between academia, industry and healthcare providers - laying the foundation for a more connected and equitable ATMP landscape.

The platform also played a key role in major European projects. In ERDERA, it advances regulatory-compliant platform technologies for safer and more cost-effective gene therapies. In the EU-funded HEAL project (coordinated by Hannover Medical School, including UMCU), EATRIS provides regulatory expertise to support development of iPSC-based therapies and preparation of the Clinical Trial Application for first-in-man studies. HEAL aligns with the IDIBELL-chaired and EATRIS vice-chaired HAPLO-Ips proposal, which develops frameworks and registries for HLA-homozygous

hiPSC lines. In EDITSCD (OSR Milan; coordinated by IMAGINE Paris), EATRIS leads innovation activities, including IP landscaping and freedom-to-operate analyses.

Education remained central. The upgraded Cell and Gene Therapy course has now engaged over 1,000 learners from 51 countries, complemented by ADVANCE courses in Rome and Ljubljana. A 2025 co-authored publication, "People, not platforms", highlighted Europe's skills gap in cell and gene therapy scale-up.

The platform addressed systemic challenges including AI in manufacturing, reimbursement models and training frameworks, facilitating nine collaborative proposals (under review). The year concluded with the launch of COST Action CINNAMON (chaired by IDIBAPS, vice-chaired by EATRIS), promoting CAR-T standardisation and training, particularly in Inclusiveness Target Countries. EATRIS also supported successful regional ATMP hub funding in Ireland and Norway, further strengthening Europe's interconnected ATMP ecosystem.

Biomarkers Platform and Personalised Medicine strategy



CO-CHAIRS:

Alain van Gool (Radboudumc, The Netherlands)

Laura García Bermejo (IRYCIS, Spain)

Andreas Scherer (FIMM, Finland)



PLATFORM MANAGER:

Emanuela Oldoni (Scientific Lead Personalised Medicine, EATRIS)

In 2025, the EATRIS Biomarkers Platform advanced new proposals, strengthened communities of practice and achieved key milestones in ongoing projects, reinforcing its role as a catalyst for collaboration and translational research.

Community building remained a central priority. Newly established communities of practice enhanced engagement and knowledge exchange across the EATRIS network while increasing the Platform's visibility within the European research ecosystem.

Under the HORIZON-INFRA-2025-01-SERV-01 call, the Platform co-developed three major proposals: EASI-OMICS (integrated multi-omics services), KIDS-SERV (accelerating paediatric clinical research) and SIRENE (assessing the impact of environmental exposures on human health). Together, these initiatives engage seven institutions as service providers, strengthening the EATRIS infrastructure. EASI-OMICS and SIRENE secured funding and will commence in Q4 2026.

The AIREACH project (Cancer Mission

Call 01-02) was also co-developed and submitted. It aimed to investigate air quality impacts on cancer risk in children and young adults through development of the Comprehensive Cancer Exposome Atlas and the Ambiomc Health Compass, translating exposomic and multi-omics data into clinical insight. Although not funded, the proposal strengthened collaboration across the community.

Momentum continued following the 2023 Biomarkers for Long COVID workshop. After the initial COST Action was unsuccessful, a revised proposal - LC-SynergiC - was submitted in 2025, demonstrating sustained commitment to patient care.

A further milestone was the "AI in Biomarker Research and Development" workshop within the Sweden Spotlight Programme, which catalysed the creation of the Digital Biomarkers Working Group. Launched in summer 2025 with around 30 experts, the group advances digital biomarker development, validation and clinical integration, focusing on digital health technologies (wearables, apps and remote monitoring), biomarker


identification and implementation, and best-practice strategies to accelerate clinical adoption.

The Platform also contributed to INFLAMomx, canSERV, EATRIS-CONNECT and PRECISEU, while strengthening collaboration with EP PerMed and the Personalized Medicine Coalition. High-level engagement included leadership roles at the Biomarkers & Precision Medicine 2025 conference (London), where the Platform organised a roundtable on future academia-industry collaboration.

In 2025, membership expanded to 108 institutions, adding six new centres across the Czech Republic, Portugal and Spain, further reinforcing pan-European expertise in biomarker development and validation.

Looking ahead to 2026, the Platform will deepen expertise in digital biomarkers, strengthen strategic partnerships and leverage flagship projects to position EATRIS as a key enabler of personalised medicine in Europe and beyond.

Imaging and Tracing



PLATFORM CHAIR:

Albert Windhorst (Amsterdam UMC, Amsterdam, The Netherlands)



PLATFORM COORDINATOR:

Sara Zullino (Scientific Lead AI for Medical Applications, EATRIS)

In 2025, community-driven initiatives remained central to the Imaging and Tracing Platform, reinforcing scientific excellence and strengthening collaboration across participating institutions.

The Tracer Factory expanded to 12 institutions across 13 countries, offering a portfolio of 33 radiotracers. Collaboration deepened through regular exchanges and participation in major international events, including the Turku PET Symposium (Finland) and the Brain & Brain PET Conference (Seoul, South Korea), enhancing visibility and fostering new cross-border partnerships. The network advanced strategic priorities by harmonising radiotracer production practices and facilitating cross-border access. Active institutional engagement remains essential to contribute technical expertise, strengthen scientific leadership and sustain this coordinated European effort.

EATRIS also played an active role in major EU-funded initiatives. Within TRUSTroke, a prospective clinical study launched in July 2025, enrolling over 600 patients across three

hospitals. UMBRELLA advanced regulatory science objectives through IDIBELL-led workshops. EUCAIM expanded by onboarding 19 new beneficiaries, including five EATRIS institutions from Norway, Spain, Latvia and the Netherlands. EATRIS and EUCAIM also co-organised a BioFIT workshop on advancing data incorporation and interoperability for Cancer Image Europe, highlighting developments in AI and bioinformatics for cancer imaging.


Compass AI launched as a European Commission flagship under the Apply AI Strategy, with EATRIS contributing translational expertise. The initiative supports safe and effective AI implementation in healthcare, particularly in cancer care and remote settings, by establishing a pan-European expert community. Compass AI will develop deployment guidelines, launch an interactive platform mapping best practices, and improve AI literacy among healthcare professionals, hospital managers and patients. EATRIS ensures outputs remain clinically relevant and aligned with European health priorities.

The Platform also contributed to European health and digital policy, including the EU Health Policy Platform Thematic Network on AI-powered imaging in precision cancer medicine (with EUCAIM), feedback to the EU Cardiovascular Health Plan and the European Strategy for AI in Science, and participation in a high-level panel at the TOGETHER4HEALTH Conference under the Danish Presidency. International visibility was strengthened through the European Congress of Radiology and the IEEE Engineering in Medicine and Biology Society.

In 2025, two institutions joined: Gregorio Marañón Health Research Institute (IiSGM, Spain) and Norwegian Medical Cyclotroncenter AS (Norway).

Looking ahead, the Platform will continue bridging technical innovation and clinical application by strengthening regulatory readiness and AI compliance frameworks, ensuring innovation remains trusted, validated and aligned with unmet medical needs.

Small Molecules



CO-CHAIRS:

Maddalena Fratelli (IRCCS Istituto “Mario Negri”, Italy)

Alfredo Budillon (IRCCS Istituto Nazionale dei Tumori G. Pascale, Italy)



PLATFORM MANAGER:

Martin de Kort (Scientific Lead Medicines Development, EATRIS)

In 2025, a growing number of Small Molecules Platform institutions engaged in the translational impact programme focused on academic drug development and drug repurposing. The flagship REMEDi4ALL project further matured towards becoming a sustainable platform, highlighted by the successful iDR25 conference in Amsterdam, which convened an expanding international community dedicated to medicines repurposing.

The REMEDi4ALL Repurposing Concierge continued to handle a steady flow of requests, exceeding 250 to date. This confirms the sustained need for a one-stop-shop providing access to repurposing expertise across the Translational Research value chain. Several projects progressed to follow-up support, contributing to a growing portfolio of collaborative

repurposing initiatives working towards regulatory approval for new uses of existing medicines in areas of high unmet medical need, while strengthening collaboration with the funders’ network.


Within the same repurposing ecosystem, the SIMPATHIC project advanced in its third year, accelerating repurposing for rare neurological, neurometabolic and neuromuscular diseases through innovative approaches. In 2025, work continued on a regulatory framework to enable approval of repurposed medicines for groups of rare diseases with shared symptoms and molecular aetiologies, using basket trial designs for clinical evaluation.

With 45 participating institutions, the Platform continues to expand its capacity and geographic reach, including the welcome of Slovakia as

a new member. Increasing attention is also being given to New Approach Methods (NAMs) as alternatives to animal models, offering improved predictivity and human relevance through organoids, patient-derived cells, organ-on-chip systems and digital models. Preparations are underway to mobilise the community and collaborate with leading organisations to promote adoption of robust, reliable NAMs for predicting safety and efficacy of candidate and existing drugs, thereby accelerating medicines development and repurposing.

To support this, EATRIS institutions have been invited to contribute to a dedicated digital symposium on NAMs, showcasing expertise and discussing challenges and trends towards full regulatory-compliant implementation of these methods.

Vaccine, Inflammation and Immune Monitoring (VIIM)



PLATFORM CO-CHAIR:

Jan Langermans (BPRC and Utrecht University, the Netherlands)

Lucia Gabriele (Istituto Superiore di Sanità, Italy)



PLATFORM COORDINATOR:

David Morrow (Scientific Lead Advanced Therapies, EATRIS)

In 2025, the EATRIS Vaccines, Inflammation and Immune Monitoring (VIIM) Platform, comprising 31 centres across Europe, continued to provide integrated scientific, technological and regulatory expertise to support vaccine developers and the broader therapeutic community. While anchored in vaccinology, its capabilities extend to antiviral development, advanced therapy medicinal products (ATMPs) and other immune-based therapeutics requiring advanced immunomonitoring. The Platform remains a key contributor to Europe’s preparedness and translational capacity in immunologically driven therapies.

Pandemic responsiveness remained a defining feature of 2025. The ISIDORE project concluded successfully in autumn, with EATRIS institutions delivering technological and regulatory services to 12 research projects developing vaccines, antivirals and diagnostics targeting pandemic-

prone pathogens. The initiative demonstrated the strength of the VIIM network in mobilising expertise rapidly, harmonising immune monitoring approaches and supporting regulatory navigation under accelerated timelines. Building on this work, the ISIDORE 2 proposal was submitted at year end, bringing together 10 VIIM centres to provide coordinated infrastructure, advanced immune monitoring technologies and regulatory expertise for future outbreak preparedness.

Beyond project delivery, the Platform contributed to shaping scientific and regulatory discourse on next-generation vaccines. EATRIS regulatory experts co-authored the 2025 publication “The new era of vaccines: scientific challenges and their regulatory needs” (Vaccine Insights 2025; 4(9), 351–365). The paper analyses the evolving landscape of vaccinology, highlighting how COVID-19 reaffirmed the central role of vaccines in global health, while advances in cancer immunotherapy

have expanded vaccine science into therapeutic domains. It underscores convergence between preventive vaccines and therapeutic cancer vaccines, where immune mechanisms are harnessed to treat established disease. Rapid advances in host immunity research, novel platforms and precision immunomonitoring tools are accelerating applications across infectious, degenerative and oncological conditions. The publication calls for adaptive regulatory frameworks that better integrate scientific innovation and regulatory requirements.

Through coordinated infrastructure, pandemic preparedness and regulatory leadership, the VIIM Platform continues to strengthen Europe’s capacity to develop safe, effective and innovative vaccines and immune-based therapies, ensuring that scientific progress is matched by regulatory readiness and translational delivery.

featured publications

Featured publication from EATRIS

Multi-omics quality assessment in personalised medicine through European infrastructure for translational medicine (EATRIS): an overview



Key Messages:

This publication outlines a coordinated European framework for multi-omics quality assessment within EATRIS, strengthening standardisation, reproducibility and cross-site comparability in translational research. By aligning analytical workflows, reference materials and quality metrics across institutions, it provides practical foundations for robust biomarker discovery and implementation in personalised medicine.

Summary:

The increasing integration of genomics, transcriptomics, proteomics and metabolomics into clinical research has highlighted the urgent need for harmonised quality standards. Within the EATRIS infrastructure, a multi-omics working group developed a structured approach to quality assessment that spans experimental design, data generation, bioinformatics analysis and reporting.

The publication describes practical measures to enhance reproducibility, including inter-laboratory benchmarking, shared reference samples, standard operating procedures and transparent metadata reporting. It emphasises the importance of coordinated infrastructure support to ensure that omics-derived biomarkers are analytically valid, clinically meaningful and suitable for regulatory translation.

By embedding quality control within infrastructure-level services rather than isolated projects, EATRIS demonstrates how research infrastructures can accelerate safe and reliable implementation of personalised medicine across Europe. The framework provides a scalable model for multi-country collaboration and strengthens Europe's capacity for high-quality translational omics research.

Citation:

EATRIS-Plus Multi-omics Working Group, Alonso-Andrés P, Baldazzi D, et al. Multi-omics Quality Assessment in Personalized Medicine Through European Infrastructure for Translational Medicine (EATRIS): An Overview. *Phenomics*. 2025. doi:10.1007/s43657-024-00170-0.

Featured publication from an EATRIS institute in Finland

Single-cell lineage tracing uncovers resistance evolution and predicts immunotherapy efficacy in glioblastoma

Key messages:

This study applies single-cell lineage tracing to map tumour evolution and therapy resistance in glioblastoma, enabling prediction of immunotherapy response and supporting precision oncology strategies.

Summary:

Glioblastoma remains one of the most aggressive and treatment-resistant cancers. Understanding how tumour cells evolve under therapeutic pressure is essential to improve outcomes. In this study, researchers combined single-cell sequencing technologies with lineage tracing approaches to monitor clonal dynamics in glioblastoma.

The analysis revealed distinct evolutionary trajectories associated with treatment resistance. Importantly, specific cellular states and clonal expansions correlated with immunotherapy response, providing predictive insight into which patients may benefit from immune-based treatments.

By integrating high-resolution molecular profiling with functional validation, the work demonstrates the clinical utility of advanced single-cell technologies in translational oncology. The findings support infrastructure-enabled precision medicine approaches, where biomarker-informed stratification guides treatment decisions and improves therapeutic efficacy.

Citation:

Eriksson J, Zheng S, Popa M, et al. Single-Cell Lineage Tracing Uncovers Resistance Evolution and Predicts Immunotherapy Efficacy in Glioblastoma. *Cancer Res.* 2025. doi:10.1158/0008-5472.CAN-24-3753.

Featured publication from an EATRIS institute in the Czech Republic

It's a match: use of the radionuclide theranostic pair $^{133}\text{La}/^{225}\text{Ac}$ for radiopharmacological characterisation of EGFR-targeted single-domain antibodies

Key messages:

This study validates the theranostic radionuclide pair $^{133}\text{La}/^{225}\text{Ac}$ for EGFR-targeted single-domain antibodies, advancing precision radiopharmacy by linking diagnostic imaging and targeted alpha therapy.

Summary:

Theranostics combines diagnostic imaging and targeted radionuclide therapy using matched isotopes. This study evaluates the radionuclide pair ^{133}La (imaging) and ^{225}Ac (alpha therapy) in the context of EGFR-targeted single-domain antibodies.

The authors demonstrate robust radiolabelling, favourable pharmacokinetics and tumour targeting properties. Imaging with ^{133}La enables non-invasive assessment of biodistribution, while ^{225}Ac delivers potent targeted cytotoxicity. The matched isotope strategy allows patient-specific planning and optimisation of therapeutic dosing.

The work highlights how radiopharmaceutical innovation, supported by specialised infrastructure, can accelerate translation from preclinical validation to clinical application. It strengthens Europe's leadership in imaging and targeted radionuclide therapy and illustrates the integration of diagnostics and therapeutics within precision oncology.

Citation:

Trommer J, Ullrich M, Reissig F, et al. It's a match: use of the radionuclide theranostic pair $^{133}\text{La}/^{225}\text{Ac}$ for radiopharmacological characterisation of EGFR-targeted single-domain antibodies. *EJNMMI Radiopharm Chem.* 2025. doi:10.1186/s41181-025-00354-7.

Featured publication from an EATRIS institute in the Netherlands

SIMPATHIC: Accelerating drug repurposing for rare diseases by exploiting SIMilarities in clinical and molecular PATHology

Key messages:

SIMPATHIC introduces a structured framework to identify drug repurposing opportunities for rare diseases by analysing shared molecular and clinical features across conditions.

Summary:

Rare diseases often lack dedicated drug development programmes due to limited patient populations. SIMPATHIC proposes a data-driven strategy to accelerate drug repurposing by identifying similarities in clinical presentation and molecular pathology across diseases.

The framework integrates multi-omics data, clinical phenotypes and computational analysis to uncover shared mechanisms that may respond to existing therapeutics. By systematically mapping cross-disease similarities, the approach expands therapeutic options for underserved patient groups.

The study exemplifies collaborative translational research across Europe, linking computational discovery, biological validation and clinical relevance. It reinforces the role of research infrastructures in enabling cross-border data integration and accelerating repurposing strategies for rare conditions.

Citation:

van Karnebeek CDM, Müller AR, Benkemoun L, et al. SIMPATHIC: Accelerating drug repurposing for rare diseases by exploiting SIMilarities in clinical and molecular PATHology. *Mol Genet Metab*. 2025. doi:10.1016/j.ymgme.2025.109073.

Featured publication from an EATRIS institute in the Netherlands and Italy

Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations

Key messages:

This publication demonstrates a targeted RNA sequencing strategy to detect clinically actionable expressed mutations, improving molecular stratification in precision oncology.

Summary:

While DNA sequencing identifies genomic variants, not all mutations are transcriptionally active. This study presents a targeted RNA-Seq approach that focuses on expressed mutations, improving identification of clinically actionable targets.

The method enhances sensitivity for low-frequency variants and confirms biological relevance by detecting transcript-level expression. The authors demonstrate its utility in oncology settings, supporting improved patient stratification and therapy selection.


By bridging molecular diagnostics and clinical implementation, this work contributes to robust, reproducible precision medicine pipelines. It highlights the importance of validated, standardised analytical workflows in ensuring that molecular findings translate into effective clinical decision-making.

Citation:

Li D, Li J, Johann DJ, et al. Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations. *NPJ Precis Oncol*. 2025. doi:10.1038/s41698-025-00993-8.

Featured publication from an EATRIS institute in Finland and Norway

Computational drug repurposing: approaches, evaluation of in silico resources and case studies



Key message:

This Nature Reviews Drug Discovery article provides a comprehensive evaluation of in silico drug repurposing tools and demonstrates their application through REMEDI4ALL case studies.

Summary:

Computational approaches have become central to drug repurposing, yet the landscape of available tools is complex and heterogeneous. This review systematically categorises in silico repurposing methods, evaluates their strengths and limitations, and proposes best-practice guidance.

Drawing on REMEDI4ALL case studies, the authors illustrate how computational predictions can be integrated with experimental validation and clinical insight. The review addresses data quality, benchmarking, transparency and reproducibility, reinforcing the need for structured evaluation of digital resources.

By combining methodological analysis with real-world applications, the publication strengthens Europe's position in data-driven translational medicine. It provides a reference framework for researchers, clinicians and regulators working to accelerate safe and effective drug repurposing.

Citation:

Tanoli, Z., Fernández-Torras, A., Özcan, U.O. et al. Computational drug repurposing: approaches, evaluation of in silico resources and case studies. *Nat Rev Drug Discov.* 2025. doi:10.1038/s41573-025-01164-x.

Featured publication from an EATRIS institute in Finland

Establishing a GMP-compliant manufacturing process and phase-appropriate analytics for early development of a FiCAR T-cell product with a novel CAR spacer



Key messages:

This study establishes a GMP-compliant manufacturing workflow and analytical framework for early-phase development of a novel CAR T-cell product.

Summary:

Advanced therapy medicinal products (ATMPs) require robust manufacturing and quality control processes to ensure safety and regulatory compliance. This study describes the development of a GMP-compliant production process for a FiCAR T-cell product incorporating a novel CAR spacer design.

The authors detail manufacturing optimisation, quality testing and phase-appropriate analytics, demonstrating consistency, safety and functional potency. By integrating regulatory considerations from early development stages, the work facilitates smoother transition to clinical trials.

The publication highlights the critical role of specialised translational infrastructures in bridging laboratory innovation and clinical application. It strengthens European capacity in ATMP manufacturing and supports scalable, compliant development of next-generation cell therapies.

Citation:

Luostarinen, A., Vuorela, A., Kerkelä, E. et al. Establishing a GMP-compliant manufacturing process and phase-appropriate analytics for early development of a FiCAR T-cell product with a novel CAR spacer. *Sci Rep.* 2025. doi:10.1038/s41598-025-92736-9.

Featured publication from an EATRIS institute in the Czech Republic

Less reactogenic whole-cell pertussis vaccine confers protection from *Bordetella pertussis* infection



Key message:

This study demonstrates that a modified whole-cell pertussis vaccine reduces reactogenicity while maintaining protective efficacy.

Summary:

Although whole-cell pertussis vaccines provide durable protection, their reactogenicity has limited acceptance. This study evaluates a modified formulation designed to reduce adverse reactions while preserving immunogenicity.

In preclinical models, the vaccine induced protective immune responses against *Bordetella pertussis* infection with improved safety profiles compared to traditional formulations. Immunological analyses revealed balanced cellular and humoral responses.

The findings support the development of improved vaccine strategies that combine efficacy with enhanced tolerability. The study exemplifies translational vaccine research aligned with public health needs and infrastructure-supported development pathways.

Citation:

Škopová K, Holubová J, Bočková B, et al. Less reactogenic whole-cell pertussis vaccine confers protection from *Bordetella pertussis* infection. *mSphere*. 2025. doi:10.1128/msphere.00639-24.

Featured publication from the EUCAIM consortium

Empowering cancer research in Europe: the EUCAIM cancer imaging infrastructure



Key messages:

EUCAIM establishes a federated European cancer imaging infrastructure, enabling large-scale data sharing, AI development and cross-border collaboration.

Summary:

The European Cancer Imaging Initiative (EUCAIM) aims to connect imaging data repositories across Europe to accelerate cancer research and artificial intelligence development. This publication describes the infrastructure architecture, governance model and technical framework underpinning the initiative.

By harmonising imaging data standards, metadata structures and secure access mechanisms, EUCAIM enables federated analysis while respecting privacy and regulatory requirements. The infrastructure supports development and validation of AI tools for cancer detection, prognosis and therapy monitoring.

EUCAIM represents a major step toward integrated European digital health research. It demonstrates how coordinated infrastructure investment can enhance data-driven oncology, promote collaboration and strengthen Europe's leadership in imaging-based translational research.

Citation:

Marti-Bonmati L, Blanquer I, Tsiknakis M, et al. Empowering cancer research in Europe: the EUCAIM cancer imaging infrastructure. *Insights Imaging*. 2025. doi:10.1186/s13244-025-01913-x.

Featured publication from an EATRIS institute in Spain

T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes

Key message:

This study characterises host T-cell responses against CD19-targeted CAR T therapy (ARI-0001), providing insight into immune-mediated effects on treatment persistence and outcomes.

Summary:

Chimeric antigen receptor (CAR) T-cell therapies have transformed treatment of B-cell malignancies, yet variability in durability and response remains a challenge. This study investigates host immune responses directed against the CAR construct in patients treated with ARI-0001.

The authors identify T-cell-mediated immune responses that may influence CAR T-cell persistence and clinical outcomes. Understanding these immunogenic mechanisms is essential for improving long-term efficacy and reducing relapse risk.

The findings inform next-generation CAR design and immune monitoring strategies. By linking mechanistic immunology with clinical outcomes, the work advances translational cell therapy development and supports optimisation of advanced therapy medicinal products in Europe.

Citation:

Bartoló-Ibars A, et al. T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes. 2025. [PubMed PMID: 40987492](#).

Digital Transformation



In 2025, EATRIS advanced its Digital Transformation strategy, with EATRIS-CONNECT serving as the central driver. Two community engagement schemes - the DT Expert and DT Champions programmes - were launched to strengthen coordination across national nodes and embed digital expertise throughout EATRIS projects. Together, these initiatives consolidated digital activities across the network and reinforced EATRIS' role within Europe's digital health ecosystem, including engagement with the European Open Science Cloud (EOSC), the European Health Data Space (EHDS) and policy discussions related to the AI Act.

A major focus was the development of the EATRIS Digital Hub, a contextual large language model platform integrating trusted community knowledge with retrieval-augmented generation capabilities. During 2025, a proof-of-concept was delivered and progress made on the technical architecture, governance framework and content curation model, preparing the Hub for launch in Q2 2026. This work establishes the foundation for a reliable, community-driven digital service supporting translational research across Europe.

Within EATRIS-CONNECT, workflows for AI-enabled diagnostics were developed and received ethical approval. This enabled the creation of a reusable ethics protocol template for AI diagnostics, facilitating future deployment across projects and national nodes. Related outputs will be integrated into the Digital Hub to support researchers implementing AI-enabled technologies.

EATRIS continued to contribute to the EOSC ecosystem through the OSCARS project

and supporting the establishment of Competence Centres across Europe. A 2025 preprint highlighted EATRIS' contribution to advancing Open and FAIR Science. Collaboration with ERINHA and the Life Science Research Infrastructure Cluster further supported development of a shared framework for Competence Centres. In parallel, EATRIS contributed to a Horizon Europe proposal focused on data stewardship skills, training and professionalisation.

Under the European Mission on Cancer, EATRIS plays a leading role in the CANDLE project, coordinating the co-creation and implementation of maturity models for National Cancer Data Nodes in collaboration with ELIXIR. These structured frameworks support organisations in assessing and progressively strengthening their data capabilities. Strong synergies were established with UNCAN-Connect, EU-CIP and ECHOS, reinforcing EATRIS' strategic role in Europe's cancer data landscape.

Digital and data-driven activities were further strengthened through the IHI-funded RealiseD project. Together with Sanofi, EATRIS co-leads the Innovation Readiness work package and co-hosted a workshop in Amsterdam to inform development of a Rare Disease Playbook.

Overall, 2025 marked a consolidation phase for Digital Transformation, strengthening infrastructure, governance and ethical readiness while positioning EATRIS for wider delivery and impact in 2026 and beyond.

Repurposing at EATRIS

Drug repurposing is increasingly recognised as a strategic, efficient and patient-centred approach to addressing unmet medical needs. At EATRIS, repurposing is a core pillar of the mission to accelerate translation of scientific discoveries into tangible patient benefit.



For more than a decade, EATRIS has championed medicines repurposing by building bridges between academia, clinicians, regulators, funders and industry. This coordinated approach enables existing compounds to be redeveloped for new indications, reformulated for different populations or applications, and validated for clinical use. Through this ecosystem-building role, EATRIS has contributed to shaping a European environment in which repurposing is embedded as a structured development pathway.

A defining milestone is REMEDI4ALL, the European flagship initiative on repurposing coordinated by EATRIS and funded under Horizon Europe. REMEDI4ALL has established an integrated support framework connecting expertise across sectors and countries while lowering scientific, regulatory and operational barriers. Key components include:

A Digital Academy to train the next generation of repurposing leaders

A Stakeholder Forum aligning public and private perspectives

A Funders' Network strengthening coordination and long-term sustainability

A Repurposing Concierge providing tailored scientific, regulatory and business guidance



Together with access to EATRIS' platforms and infrastructure, these instruments support projects at all stages of development and strengthen Europe's capacity to bring repurposed therapies to patients.

Training and capacity building remain central. Through TMex and the TransMed Academy, EATRIS equips researchers with the skills required to design, validate and implement repurposing strategies. Innovative tools such as the REPURPOLIS educational board game illustrate the complexity of translational pathways and emphasise the importance of multidisciplinary, patient-centred and regulatory-compliant development, guided by clearly defined stage gates and objective decision criteria.

EATRIS also advances research and innovation in this field. Projects such as SIMPATHIC, an EU-funded Horizon Europe initiative, explore new methodological approaches, while participation in global initiatives including NewFound highlights the international dimension of repurposing. At national level, collaboration with partners such as FAST.NL/RARE.NL strengthens the ecosystem, including dialogue on sustainable access, pricing and reimbursement models.

Beyond project implementation, EATRIS contributes to policy and regulatory discussions linked to evolving European pharmaceutical legislation. Publications, expert workshops on bringing repurposed medicines to patients and the annual iDR conference series - recognised by international media including The New York Times and Forbes - reflect both thought leadership and practical progress.

Through coordinated infrastructure, capacity building and policy engagement, EATRIS positions repurposing as a scalable and sustainable strategy for delivering innovative and accessible medicines across Europe and beyond.

projects

Overview of Projects in 2025

EATRIS is a partner in the following projects:

CANDLE - Improving existing health data infrastructures in cancer research		JUN 01 2025 MAY 31 2028
CanSERV - Providing cutting edge cancer research services across Europe		SEPT 01 2022 AUG 31 2025
Compass AI – Uniting Europe to enable safe, ethical, and effective AI adoption in healthcare through collaboration, standards, and real-world implementation		OCT 01 2025 SEPT 30 2029
EATRIS-CONNECT – Digital transformation as a tool to accelerate translational medicine		MAY 01 2024 APR 30 2027
EDITSCD - Assessing efficacy and safety of genome editing approaches for sickle cell disease		SEPT 01 2022 AUG 31 2027
EOSC4Cancer - A European foundation to accelerate data-driven cancer research		SEPT 01 2022 FEB 28 2025
ERDERA - European Rare Diseases Research Alliance		SEPT 01 2024 AUG 31 2034
ERIC FORUM 2 - Strengthening the coordination and networking of the established European Research Infrastructure Consortia (ERICs)		SEPT 01 2023 AUG 31 2027
ERICA - Strengthening the research and innovation capacity of the European Reference Networks (ERNs)		MAR 01 2021 FEB 28 2025
EUCAIM - European federation for cancer images		JAN 01 2023 DEC 31 2026
HAPLO-iPS - Generation of Human Induced Pluripotent STEM Cells from Haplo-selected Cord Blood Samples		OCT 11 2022 OCT 10 2026
HEAL - HLA-homozygous iPSC-cardiomyocyte aggregate manufacturing technologies for allogeneic cell therapy to the heart		OCT 01 2021 FEB 28 2026

- Training
- Industry Collaborations
- Personalised Medicine
- Quality and Reproducibility
- Research Infrastructure Development

iNEXT Discovery - Infrastructure for transnational access and discovery in structural biology		FEB 01 2020 JUL 31 2024
iRISE - Improving reproducibility in science		SEPT 01 2023 AUG 31 2026
ISIDORé - Integrated Services for Infectious Diseases Outbreak Research		FEB 01 2022 JUL 31 2025
OSCARS - Open Science Clusters' Action for Research and Society		JAN 01 2014 DEC 31 2027
PRECISEU - PeRsonalised medicine Empowerment Connecting Innovation ecoSystems across EUrope		JUL 01 2024 JUN 30 2029
RealiseD – Comprehensive methodological and operational approach to clinical trials in rare and ultra-rare diseases		JAN 01 2025 DEC 31 2029
Recognised - Retinal And Cognitive Dysfunction in Type 2 Diabetes		JAN 01 2020 DEC 31 2024
REMEDI4ALL - Building A Sustainable European Innovation Platform to Enhance the Repurposing of Medicines for All		SEPT 01 2022 AUG 31 2027
RITIFI - Research Infrastructure Technology Infrastructure for Impact		APR 01 2023 DEC 31 2025
SIMPATHiC - Accelerating Drug Repurposing for Rare Neurological, Neurometabolic And Neuromuscular Disorders by Exploiting Similarities in Clinical And Molecular Pathology		JUL 01 2023 JUN 30 2028
TRUSTroke - Trustworthy Ai For Improvement Of Stroke Outcomes		MAY 01 2023 APR 30 2027
UMBRELLA - Unleashing a CoMprehensive, Holistic and Patient Centric Stroke Management for a Better, Rapid, AdvancEd and PersonaLised Stroke Diagnosis, TreAtment and Outcome Prediction		OCT 01 2024 SEPT 30 2029

Spotlight on Newly Launched Projects in 2025

In 2025, EATRIS further strengthened its role in advancing translational medicine across Europe by participating in two newly launched Horizon Europe projects: COMPASS-AI and RealiseD. These initiatives address two critical and rapidly evolving areas in healthcare – the responsible integration of AI into clinical practice and the optimisation of clinical trial methodologies for rare and ultra-rare diseases.



Compass AI

COMPASS-AI Advancing Trustworthy AI in Healthcare

COMPASS-AI, coordinated by Maastricht University (2025-2029), aims to create a coordinated European framework for the safe, ethical, and evidence-based use of AI in healthcare. The project brings together patients, clinicians, researchers, industry, and policy-makers to align existing AI initiatives, develop practical guidelines, and strengthen governance and patient involvement.

EATRIS leads the work package focused on building and coordinating a multidisciplinary expert community, ensuring stakeholder-driven input into guidelines and digital tools. EATRIS also contributes to evaluation, policy recommendations, and long-term sustainability, helping to align AI implementation with European health priorities.

Realise D

RealiseD Improving Clinical Trials for Rare Diseases

RealiseD, coordinated by Sigmund Freud Privatuniversität Wien (2025-2029), aims to transform clinical trial design for rare and ultra-rare diseases. By refining innovative statistical methods and strengthening operational procedures – including patient referral pathways and site certification – the project seeks to accelerate drug development while maintaining robust evidence standards.

EATRIS leads the work package on “Innovation Readiness and Playbooks”, developing practical resources to support the design and implementation of novel trial approaches. These tools will be tested with stakeholders and supported by a sustainability plan to ensure long-term impact.

Through COMPASS-AI and RealiseD, EATRIS continues to strengthen Europe’s translational research ecosystem, advancing digital innovation, methodological excellence, and patient-centred approaches across healthcare.

From Crisis to Preparedness: The Lasting Legacy of ISIDORe and the Strength of EATRIS



In 2025, the ISIDORe project concluded as a landmark European initiative reshaping preparedness and response to infectious disease threats. Emerging from lessons of the COVID-19 pandemic, ISIDORe demonstrated that Europe's strength lies in coordinated, connected research infrastructure alongside scientific excellence.



Funded by the Horizon Europe programme and coordinated by ERINHA, ISIDORe brought together a core consortium of 17 European research infrastructures and networks, engaging over 150 access providers across 31 countries and offering a large-scale, coordinated response to infectious disease threats. Through a single access point, scientists from academia, public health and industry accelerated work on epidemic-prone pathogens and countermeasures including vaccines, antivirals and diagnostics (Cordis, Dec 2025). Alignment with the European Commission and the World Health Organisation ensured reinforcement of outbreak response, surveillance and risk assessment at European and global level.

ISIDORe responded rapidly to emerging threats. An early emergency call addressed SARS-CoV-2 variants of concern, followed by mobilisation during the Mpox outbreak and additional calls targeting pathogens with epidemic or pandemic potential. Access to services was free of charge and based on scientific excellence, feasibility and ethical compliance. Over 70 research initiatives were supported.

Standout achievements included:

Targeted surveillance of Crimean-Congo haemorrhagic fever virus (CCHFV) in Corsica, strengthening early-warning capacity.

Rapid development of a point-of-care diagnostic tool during the 2022 Mpox outbreak. A Funders' Network strengthening coordination and long-term sustainability

Regulatory guidance and clinical support enabling development of a fast-acting formulation blocking SARS-CoV-2 and influenza infection



ISIDORe, represented by the European Research Infrastructure on Highly Pathogenic Agents, is now strategically anchored within the European Pandemic Preparedness Partnership "Be Ready Now," launching in 2026, ensuring continuity of scientific readiness.

EATRIS, through its Vaccine, Inflammation and Immune Monitoring (VIIM) Platform, played a central translational role. Four VIIM members and EATRIS regulatory experts delivered services including Phase II immune phenotyping for adoptive cell therapies, evaluation of COVID-19 vaccine effectiveness in healthcare workers, cytokine analyses linked to influenza A responses, and regulatory advice for seven projects advancing COVID-19 vaccines, repurposed tuberculosis treatments and silkworm-based Ebola vaccine production.

Capacity was further strengthened through over €200,000 secured by IGTP and GIMM to develop new services, including the Integrated Antiviral Discovery Platform (Res4PrioPath).

ISIDORe has shown that coordinated open access to European infrastructures accelerates science and strengthens preparedness. With ISIDORe 2.0 now granted and set to begin, Europe continues building the foundation for sustained outbreak readiness.

services and activities

Innovation Management and Business Development

In 2025, EATRIS strengthened the strategic alignment between Innovation Management (IM) and Business Development (BD), recognising that closer integration is essential to support translational research and build sustainable collaborations. Previously operating as complementary but distinct functions, IM and BD were consolidated into a more integrated and agile innovation support model.

This alignment improved the pathway from industry engagement to collaboration, enabling better prioritisation of opportunities, stronger coordination with external stakeholders, and enhanced support for researchers, charities, funders and SMEs. IM and BD activities were also aligned with education and training portfolio of activities to ensure innovators are equipped to navigate the translational ecosystem. Importantly, EATRIS services were accepted into the European Innovation Council (EIC) Partner Catalogue, marking a significant step toward deeper integration into the EU innovation ecosystem and increased visibility to start-ups, SMEs, and industry partners seeking translational collaboration.

In 2025, through EATRIS-CONNECT, the Spotlight Programme, training and mentoring initiatives, EATRIS reached hundreds of researchers and early-career academics, enhancing visibility and translational research capabilities across Member States. Efforts focused on capacity building, proposal development and digital transformation. As a result, EATRIS was a partner in 28 proposal submitted and 24 consortium building reports were generated; and over 90 academic led translational research projects (ERDERA, REMEDI4ALL concierge) were mentored.

Throughout the year, EATRIS leveraged participation in major EU and regional initiatives with strong industry engagement, including the ERDERA Accelerator, Biotech Booster, BIOCAT collaborations and IHI projects, to strengthen visibility and partnerships. Relationships among EATRIS Expert Centres were strengthened through bimonthly meetings, joint event participation and active promotion of consortium-building opportunities across national nodes.

Expanding collaboration with charitable organisations and funding bodies remained a priority. EATRIS delivered Translational Assessments, Regulatory Guidance, Expert Advice and Mentoring across multiple disease areas. Key partnerships included the Prinses Beatrix Spierfonds (Pompe disease), ReumaNL, the Dutch Brain Foundation (Hersenstichting), Fundación “la Caixa” (CaixaImpulse) and the Asociación Española Contra el Cáncer (AECC). Notably, EATRIS supported eleven proposals under AECC’s IMPACTO initiative, resulting in a long-term collaboration agreement extending into 2026.

Key achievements in 2025 included expanded partnerships with major European charities, delivery of over 22 Translational Assessments and Expert Advice assignments, and long-term agreements with AECC and Fundación “la Caixa”. In 2026, EATRIS will continue supporting funders while expanding services to include consortium co-creation, incubator and accelerator design, and stronger links to the EATRIS research and innovation community, including strategically relevant SMEs.

Summary of activity

SERVICES	2022	2023	2024	2025
Grant support service				
• Consortium building	22	21	24	21
• EATRIS C&S as partner	13	17	31	42
• Letter of support	5	4	10	23
• Project Advisory Board	NA	1	5	2
Research service	28	8	8	11
Translational assessment/Expert advice	29	29	10	22
Industry partnering	3	-	1	-
Mentoring	15	84	57	90
Hub management	1	1	1	1
INCOME C&S OFFICE	2022	2023	2024	2025
Service fees (audited financial report)	€ 53,432	€ 115,413	€ 142,401	€ 196,755
Grants	€ 1,618,068	€ 2,260,992	€ 2,094,077	€ 2,226,305
INCOME INSTITUTIONS (BUDGET NEGOTIATED)	2022	2023	2024	2025
EATRIS affiliated partners	€ 228,797	€ 55,875	€ 4,388,204.00	€ 3,160,726.70
Research services	€ 8,217,239	€ 341,373	€ 172,478.28	€ 177,280.00
Users (calculated from node activity reports)”	2,620,121	2,640,373	31,643	8,480

Spotlight on Mentoring at EATRIS

Translating discovery into clinical application remains one of the greatest challenges in biomedical research. Regulatory complexity, development risks and limited access to specialist expertise can delay or derail promising ideas. Mentoring is therefore a core pillar of EATRIS' mission, supporting researchers and innovators with clarity, confidence and a strong focus on patient benefit.



EATRIS offers one integrated mentoring service spanning the full translational pathway. This service is accessible through different routes. In principle, mentoring is available as a paid service to charities, funders and other organisations seeking independent, high-level translational expertise. In addition, researchers can currently access mentoring free of charge through three EU-funded programmes.

In 2025, EATRIS further expanded its mentoring offer, providing tailored, confidential guidance delivered by international experts across the translational pathway. Open to all therapeutic areas, mentoring supports academic researchers, clinicians, early-stage SMEs, biotech innovators and patient organisations working to bring research into practice.

Access to free mentoring is currently provided through three European partnerships:



ERDERA

Mentoring for Rare Disease Projects

Through the European Rare Disease Ecosystem and Research Alliance (ERDERA), EATRIS provides mentoring for rare disease projects, from early planning through post-funding implementation. Researchers receive targeted advice on translational feasibility, regulatory pathways, manufacturing, quality, intellectual property, and clinical development. Importantly, mentoring is informed by close collaboration with rare disease experts and patient communities, helping ensure that scientific excellence is aligned with real patient needs.



REMEDi4ALL

Mentoring for Drug Repurposing

Drug repurposing offers faster, more cost-effective routes to patient benefit, but brings its own regulatory, scientific, and strategic challenges. The REMEDI4ALL Repurposing Concierge acts as a central access point for mentoring, beginning with an introductory consultation and leading to tailored support. Projects benefit from multidisciplinary expertise spanning science, regulation, patient engagement, business strategy, partnership building, and funding navigation, helping promising repurposing ideas become actionable development pathways.



ERA4Health

Mentoring for Translational Health Projects

Within the ERA4Health partnership, EATRIS provides innovation mentoring to full proposal applicants, strengthening the translational and societal impact of health research. Support combines personalised mentoring sessions with training and access to the EATRIS Innovation Management Toolbox, guiding projects from design through implementation and helping applicants maximise their translational potential.

Alongside these EU-funded routes, EATRIS works directly with charities, funders and patient organisations through commissioned mentoring services, enhancing the translational impact of funding programmes and individual projects. In all cases, the aim remains the same: proposals that are scientifically robust, clinically relevant and positioned for real-world success.

Across programmes, therapeutic areas and project stages, EATRIS mentoring has become a core mechanism for strengthening translational research in Europe. By providing timely, independent and expert guidance, EATRIS helps turn promising ideas into credible development pathways with greater potential to reach patients and deliver societal value. In this way, mentoring is not simply a service offer - it is a strategic contribution to a stronger, more connected European translational ecosystem.



Advocacy and Partnerships

In 2025, advocacy and strategic partnerships remained central to EATRIS' role as a European research infrastructure committed to accelerating patient-centred translational research. Throughout the year, EATRIS strengthened its engagement with policy-makers, regulators, international partners, patient organisations and peer infrastructures, reinforcing its position as a trusted interlocutor at the interface of science, policy and society.

Policy engagement and regulatory science

EATRIS maintained a strong and consistent presence in European policy dialogue in 2025, contributing expertise grounded in operational experience across the translational medicine lifecycle. The organisation responded to a wide range of European Commission consultations, including on the EU Life Sciences Strategy, the Strategy for Research and Technology Infrastructures, the Strategy for AI in Science, the Biotech Act, the Critical Medicines Act and the EU Cardiovascular Health Plan. Across these contributions, EATRIS consistently advocated for the recognition of research infrastructures as key implementation actors, essential to bridging policy ambition to execution.

Regulatory engagement continued to be a distinctive strength. Through active participation in initiatives such as ACT-EU and COMBINE, and sustained collaboration with the European Medicines Agency (EMA), EATRIS worked to ensure that academic and infrastructure perspectives were reflected in ongoing regulatory modernisation efforts. EATRIS' role as an EMA Collaborating Expert enabled deeper insight into the challenges faced by academic developers when navigating regulatory pathways, informing both advocacy positions and practical guidance delivered through EATRIS services.

European and international partnerships

At European level, EATRIS further consolidated its collaboration within the Alliance of Medical

Research Infrastructures (EU-AMRI), working alongside ECRIN and BBMRI to promote joint advocacy on sustainability, interoperability, and patient centric research. Through engagement in the ERIC Forum, ESFRI-related activities and the RITIFI project, EATRIS contributed to discussions on the future of the European research infrastructure and technology landscape, including funding, governance and long-term resilience.

Internationally, 2025 marked a renewed momentum in global collaboration. EATRIS hosted the annual meeting of the Translation Together (TT) alliance in Amsterdam, bringing together partners from Europe, the United States, Japan and Brazil, including NCATS (NIH), LifeArc, AMED and Fiocruz. The meeting reaffirmed shared commitments to advancing translational science through data sharing, harmonised practices and patient-centred innovation, and revitalised the alliance's strategic roadmap. EATRIS' global footprint also grew through collaboration with the Personalized Medicine Coalition (PMC) in the United States, deepening dialogue on regulatory alignment and PERMED adoption.

Partnerships with organisations such as CERN and the Critical Path Institute (C-Path) deepened further in 2025. Joint activities with CERN within projects such as UMBRELLA and TRUSTroke strengthened collaboration on federated data approaches, ethical and privacy-preserving AI, and regulatory readiness while EATRIS contributed to the Rare Diseases Moonshot white paper led by C-Path, reinforcing shared priorities around data integration and translational preparedness.



Patient engagement and societal dialogue

Patient and citizen engagement remained a core pillar of advocacy. The Patient Engagement Resource Centre (PERC) expanded its support through guidance, tools and case studies for meaningful involvement across the research lifecycle. Within REMEDI4ALL, patient perspectives shaped demonstrator projects, particularly in rare diseases. The International Drug Repurposing Conference (iDR25) convened over 300 participants, including strong representation from patient groups, regulators and funders. Through EATRIS-CONNECT, workshops addressed patient views on data use, AI in healthcare and the EHDS, ensuring societal perspectives informed both technical development and policy positioning.

Visibility and influence

EATRIS participated in high-level discussions within the G7 Group of Large Research Infrastructures, ERIC Forum, ESFRI, EU Parliament workshops and European Commission events on digital health, AI, critical medicines and infrastructure sustainability. Engagement on Framework Programme 10 (FP10) emphasised the role of research infrastructures in implementation, validation, scale-up and long-term impact.

Visibility was reinforced through features in Forbes highlighting REMEDI4ALL and iDR25, and through Springer Nature's recognition of EATRIS' work on inclusive research practices, sex- and gender-aware approaches and reproducibility.

Q&A with Dr Florence Bietrix

From discovery to real-world impact in
Research Communities by Springer Nature

In 2025, Florence Bietrix (Deputy Director to the Executive Board, EATRIS) was appointed Section Editor for the Translational Process section of the Journal of Translational Medicine. In this Q&A, she reflects on her scientific background, the importance of strengthening the translational process, and its relevance for sustainable and inclusive health innovation.



Please tell us about yourself.

I am a translational scientist by training. I earned my PhD in physiopathology in Toulouse, where I studied the mechanisms underlying intestinal cholesterol absorption and cardiovascular disease. My career subsequently developed in France and the Netherlands, gradually evolving from laboratory research towards strategic and enabling roles in translational science.

Over time, my focus has centred increasingly on the translational process itself — how to move biomedical discoveries efficiently and responsibly into healthcare applications. Women's health has become an important area of attention for me, particularly the need to better integrate sex and gender considerations into research design to reduce diagnostic gaps and improve treatment outcomes.

Since joining EATRIS in 2012, first as Scientific Programme Manager and now as Deputy Director to the Executive Board, I have contributed to strengthening a pan-European translational ecosystem focused on quality, inclusivity and patient benefit. Working within the EATRIS community continues to shape my perspective on collaborative science and shared responsibility for impact.

What makes EATRIS unique?

What makes EATRIS unique is the breadth and depth of its consortium. With more than 175 academic institutions across 15 countries, we offer access to world-class capabilities in areas such as biomarkers, advanced therapies, imaging and tracing, small molecules, vaccines, and regulatory science. The consortium helps researchers de-risk their projects and make informed decisions at each stage of the Translational Medicine value chain.

Beyond technical access, EATRIS is also a community of practice. We invest in capacity building through dedicated training and mentoring programmes aimed at supporting early-career researchers and project leaders. Helping researchers understand the requirements for validation, regulatory alignment, and patient-centric design is central to our approach.



What are some of the major challenges facing the translational process?

Fragmentation remains one of the most significant challenges. Research often takes place in disciplinary or institutional silos, limiting access to complementary expertise. In addition, critical elements such as regulatory planning, reproducibility and long-term development strategy are not always sufficiently addressed at early stages.

At EATRIS, we see how even promising projects can run into difficulties if these pieces aren't addressed early. That's why we place a lot of emphasis on mentoring, training, and helping researchers think ahead about the full development pathway.

What are your hopes for the future of translational process management?

My hope is for a future in which translational medicine is not only efficient and evidence-based, but also inclusive, sustainable, and anchored in societal values. That means moving toward a model where patients and citizens are actively involved in shaping health research and innovation not just as participants, but as co-creators of solutions that reflect their lived experiences and real-world needs.

We also need to do better in ensuring that innovations are accessible and affordable, especially for people living with neglected and rare diseases, who are often left behind by traditional development models.

Gender equality is part of this too. We need more inclusive research that takes women's health seriously and designs studies with sex and gender in mind, not just for fairness, but because it leads to better science.

And finally, I hope we continue to focus on sustainability supporting science that's transparent, reproducible, and capable of delivering long-term value for patients and health systems. Small improvements in how we design and deliver research can make a big difference over time.

Spotlight on Patients Engagement Actions

An Interview with Eliis Keidong - EATRIS Member Engagement Officer



Why is patient engagement a central focus for EATRIS?

At EATRIS, we believe that patient engagement is a fundamental element of translational research. Patients must have a meaningful role in shaping and co-creating research that affects their lives. Ultimately engaging patients as partners strengthens the relevance, quality and impact of research outcomes.

How does EATRIS support researchers in implementing patient engagement?

A key initiative is the Patient Engagement Resource Centre (PERC), which we co-developed with the European Patients' Forum (EPF) and the European AIDS Treatment Group (EATG). The PERC provides practical guidance on patient engagement to researchers across Europe. With over 7,000 users, it has become a trusted reference point. We are now expanding the platform to address patient involvement in digital and data-driven research, reflecting how research itself is evolving.

What progress was made in 2025 through EATRIS-CONNECT?

Through EATRIS-CONNECT, patient engagement activities gained further momentum. The Latvian Node at Riga Stradiņš University led two workshops exploring patient involvement in digital health, ethical considerations, and the role of patient organisations in research and innovation. An additional workshop was hosted by the Norwegian Node. These initiatives fostered dialogue between researchers, patients and policy-makers, contributing to more connected and consistent engagement practices across countries.

How does EATRIS contribute to the broader European patient engagement landscape?

We remain active through our role in the Patient Engagement Open Forum (PEOF) and our collaboration with EUPATI. This includes participation in the EUPATI Training Committee and delivery of training within the EUPATI Fellows programme for patient advocates. Complementing this, we offer free places to EUPATI Fellows on our Translational Medicine (TMex) introductory course for early-career researchers, where patient engagement in pre-clinical research is a key component. In 2025, we also contributed to dialogue on early- and pre-clinical patient engagement at the 4th Irish National Patient and Public Involvement Festival in Dublin, hosted by the Irish PPI Ignite Network.

How are patient perspectives embedded within REMEDi4ALL?

Within REMEDi4ALL, patient perspectives are embedded across European drug repurposing efforts. The Partnering Portal opened to the research community in September 2025, building on the Repurposing Concierge, which has been active since 2023. The Concierge has attracted around 60 patients, patient representatives or relatives among more than 250 enquiries. These interactions have led to partnerships under development, including the DDX3X project initiated by a patient carer and father. This represents the first external funding secured beyond EU support. In one demonstrator project, collaboration with the Osteogenesis Imperfecta community supported the development of patient-centred HTA value frameworks. Patient Champions also contribute directly to Repurposing Development Teams, and the annual REMEDi4ALL Repurposing Bootcamp provides in-person training for patient representatives.

What is the overarching goal of these patient engagement actions?

By embedding patient engagement across platforms, projects and partnerships, we continue to ensure that patient involvement is normalised in research practice and ensuring that research is carried out in co-creation with patients, not just for them.

Communications

In 2025, EATRIS Communications supported organisation-wide efforts to strengthen visibility, understanding and engagement across the translational research ecosystem. Building on a digital-first, visually led, multi-channel approach, activities focused on clearly communicating EATRIS' role, services and impact for researchers, funders, policy-makers, patients and industry. Work centred on three areas: digital presence, audience engagement and strategic events.

Strengthening Digital Presence

Significant progress was made in consolidating EATRIS' digital foundations. A new master slide deck was developed, providing a consistent visual identity and narrative structure for presentations across the organisation. Website traffic reached its highest level to date, with page views increasing by 56% compared to the previous period.

New project pages were launched, alongside a dedicated Advocacy Efforts webpage highlighting engagement with funders, charities, and policy-makers. The Spotlight Programme gained greater visibility through a dedicated landing page, while key resources such as the Patient Engagement Resource Centre (PERC), the Mentoring Service, and the TransMed Academy were further developed. Work also began on an interactive digital map to showcase ATMP capacity across Europe.

For the EATRIS-CONNECT flagship project, a dedicated communications and dissemination plan was launched, delivering branding, messaging, and a suite of promotional materials to support consistent outreach. In parallel, a mid-year assessment of gender balance in EATRIS communications demonstrated a broadly balanced representation across social media content, in line with the Gender Equality Plan.

Growing Audience Engagement

Targeted engagement activities delivered strong growth across digital channels. LinkedIn followers increased by 28%, YouTube by 12%, and Facebook by 16%. A new presence on Bluesky was established, while activity on X/ Twitter was phased out. Internally, visibility of communications outputs was improved through a dedicated Teams channel and weekly digest.

Email communications continued to perform strongly, with subscriber growth of nearly 14% for the quarterly Translational Trends update, while both the quarterly and monthly email updates maintained average open rates above 38%. Communications campaigns supported a wide range of activities, including events, training programmes, projects, new project launches, advocacy initiatives, partnerships, and EATRIS services. Community-focused actions included ongoing promotion of the Spotlight Programme, publication of over a dozen new EATRIS Meets interviews, and campaigns welcoming new Member States, including Slovakia.

Supporting Events and Strategic Visibility

Communications played a central role in promoting and delivering EATRIS-led and partner events. A key highlight was the International Drug Repurposing Conference (iDR26), held in Amsterdam on 7–8 May 2025. The sold-out event convened over 300 participants from 31 countries, featuring 71 speakers and 18 posters, with strong representation from research, patient communities, regulators, HTA bodies, health authorities and industry.


The programme addressed artificial intelligence, innovative trial designs, drug repurposing for underserved populations and pathways to patient access. International media coverage in El País, Forbes and The New York Times reinforced its global reach.

Together, these activities consolidated EATRIS' digital presence, strengthened community engagement, and extended its reach across Europe and beyond, reinforcing EATRIS' role as a leading voice in translational research.



Education and Training

In 2025, EATRIS delivered a total of 33 training activities in both online and face-to-face formats, amounting to 316 hours of live training. Training activities included another successful edition of the flagship course TMex – Translational Medicine explained. In parallel, EATRIS developed a new e-learning course on sex and gender considerations in research, maintained four existing e-learning courses, and updated the e-learning on cell and gene therapy.



“

I really enjoyed the TMex course. It was engaging and pushed me outside my comfort zone. I had to talk to so many different people, some of them very skilled and successful, and I actually enjoyed it.”

Antonina

Antonina from the Institute of Biology and Immunology of Reproduction (BAS), Sofia, Bulgaria



“

TMex has been a transformative experience. The balance between science, practical activities, and patient-centred thinking gave me tools I can use immediately in my work. I highly recommend this course to anyone involved in translational medicine.”

Liron Meidan

Patient Expert & Medical Communications Specialist

Hosted by EATRIS Slovenia in Ljubljana, the EATRIS-CONNECT Summer School 2025 brought together 31 participants from 13 countries for three days of interactive training on AI and digital health in personalised medicine. Through expert lectures, hands-on workshops and networking, participants explored topics including digital biomarkers, FAIR data, machine learning and in silico drug repurposing.



“

The face-to-face meeting of the EATRIS Training Network in Amsterdam was a great opportunity to connect with professionals working in training and career development for biomedical researchers. We exchanged successful examples of training design and organisation, and openly discussed the challenges we face in our role in our respective work environments. I particularly enjoyed the Repurpolis board game on drug repurposing that we played in the evening. It offered a fun and effective illustration of how gamification can support learning around complex topics.”

Malou Fraiture

Postdoctoral Support & Development Coordinator at Luxembourg Institute of Health (LIH)

The TransMed Academy website was updated to improve ease of navigation and visibility of the expanding training portfolio.

EATRIS educational games were delivered through 16 play sessions of REPURPOLIS and three sessions of ESCAPE to the Cloud, engaging over 445 participants and resulting in more than 850 hours of training. In addition, a new educational game focusing on advanced therapy medicinal products (ATMPs), Genetropolis, was developed in collaboration with FAST and launched on 4 November 2025.

EATRIS also delivered two editions of the Gene & Cell Development course, organised by the Slovenian and Italian nodes.

The EATRIS Training Network remained an essential activity in 2025. Regular online meetings were complemented by a face-to-face workshop focused on training offers across EATRIS institutions. The workshop facilitated the identification of common training gaps and challenges, as well as opportunities for joint content development.




Spotlight on the EATRIS e-learning course on Cell and Gene Therapy

November 2025 marked the release of an enhanced and updated version of the EATRIS e-learning course 'Cell & Gene Therapy (ATMP) Development'. The content of the four core units—addressing the key scientific, manufacturing, reimbursement, and regulatory challenges across the ATMP development cycle—was comprehensively reviewed and updated to reflect the latest developments in the field. This update was made possible through EATRIS' involvement in ERDERA, the European Rare Diseases Research Alliance.

In addition, a new fifth unit was introduced to highlight how EATRIS and ERDERA support professionals working in ATMPs and rare diseases. This unit showcases relevant services and provides practical examples of real-world application, helping learners better understand how available infrastructures and expertise can be mobilised along the translational pathway. The update also included tailored content for rare disease audiences and a refreshed learning format designed to better engage and support busy professionals navigating complex translational processes.

Accessibility was a key focus of the update, with systematic improvements implemented to ensure that all learners can fully access and benefit from the course materials. Additional resources for trainers were also included and are available for re-use by EATRIS nodes and other European stakeholders.

Since the release of the updated version, the course has been accessed by 80 learners, bringing the total number of registered learners to approximately 100 since launch.



higher res image needed



Quotes from participants who attended the e-learning course on Cell and Gene Therapy

- “ Though I already know a lot about ATMP development due to my background in academia and biotechnology, I was able to pick up quite a few novel bits of information and felt encouraged to engage with careers in this direction.”
- “ I'm currently working on a project on CAR-T cell manufacturing. This course gave me clear information and knowledge on the critical questions when working on this field.”
- “ I would apply for a job based on this training.”

financial summary

Maria Vicario- Mosaico epitelial MVP

The amounts stated below have been derived from the audited financial statements of EATRIS ERIC.

Figure 1 - Income and operating result

	Annual report 2025 €	Annual report 2024 €	Annual report 2023 €
Contributions income	1,905,755	1,710,401	1,683,413
Grant income	2,202,959	1,954.809	2,310,904
Total income	4,108,714	3,665,210	3,994,317
Salaries and wages	1,979,342	1,819,400	1,794,840
Recharge to EU projects	-1,400,993	-1,137,585	-1,137,624
Sub total staff	978,578	823,948	857,508
Personnel expenses	1,556,927	1,505,763	1,514,724
Depreciation	7,920	8,141	7,109
Other expenses	501,602	447,746	596,212
Other expenses "project costs EU"	2,004,309	1,767,908	2,036,683
Total expenses	2,513,831	2,223,795	2,640,004
Total operating result	37,956	-64,348	-160,411

Figure 2 – Analysis of the balance sheet

Below we have included an analysis of the balance sheet as at 31 December 2025 versus 31 December 2024:

	2025	2024	Analysis
Activa	€ 000	€ 000	
Tangible fixed assets	19	20	
Current receivables	351	414	
Cash at banks	2,621	2,726	Cash and banks decreased mainly due to a decrease in the current liabilities.
	2,991	3,159	
Equity & Liabilities	€ 000	€ 000	
Reserves	482	444	The reserve decreased with a net of €160K, equal to the negative result of the financial year.
Current liabilities	2,509	2,715	The amount of the current liabilities are € 1.819K, subsidies received in advance.
	2,991	3,159	

meet the community

Meet the EATRIS Coordination & Support team



Adeola Adeoti
EU Grants & Project Manager



Alicia Soler
*Lead Scientific Operations
REMEDI4ALL*



Amber Whitlock
*Operations and Administrative
Assistant*



Anna Sanchez
Head of Innovation



Anna Swan
E-Learning Specialist



Antoni Andreu
Scientific Director



Anton Ussi
Finance & Operations Director



Ben Lydall
Finance & Sustainability Specialist



Camilla Santinelli
EU Grants Administrator



Cansu Tekin
Innovation Manager



Claudia Sestito
Scientific Project Manager



Danielle Tonnesen
EU Project Manager



David Morrow
Scientific Lead Advanced Therapies



Donald Lo
Director of Medicines Development



Eliis Keidong
Member Engagement Officer



Emanuela Oldoni
Scientific Lead Personalised Medicine



Florence Bietrix
*Deputy Director to the Executive
Board*



Frank de Man
Advisor to the Executive Board



Giovanni Migliaccio
Consultant / CVBF Scientific Director



Ivette Corominas
Events Manager



Jake Fairnie
Head of Communications



Lalageh Masihi
Financial Controller



Lauranne Duquenne
Education & Training Manager



Laure Boudaud
Operations Manager



Lisa Williams
Head of Administration



Martin de Kort
Scientific Lead Medicines Development



Max Adams
Communications Manager



Moa Drugge
Human Resources Officer



Nektarios Liaskos
Data Strategy Manager



Nikoleta Efthymiopoulou
*Scientific Project Management
Assistant*



Piret Baur
Communications Manager



Rebecca Ludwig
Head of Education and Training



Rosan Kreeftmeijer-Vegter
*Scientific Lead Rare Diseases and
Regulatory Advisory*



Sara Zullino
*Scientific Lead AI for Medical
Applications*



Sarah Morgan
Training Manager



Tamara Carapina
Head of Legal and Governance



Tara Perovic
Financial Administrative Assistant




Tomás Muñoz
Junior Legal Counsel

Node Governance



Country	Board of Governors	Board of National Directors	National Coordinator
BULGARIA	Yanita Zherkova <i>Milena Glavcheva</i>	Rossitza Konakchieva <i>Rumen Pankov</i>	Georgi Georgiev
CROATIA	Jelena Ilic Dreven (Chair) <i>Mateo Ante Bosnić</i>	Fran Borovecki <i>Antonela Blažeković*</i>	Lozika Mašić
CZECH REPUBLIC	Judita Klosakova <i>Marián Hajdúch</i>	Marian Hajdúch <i>Katerina Sromova</i>	Erik Dvorak
FINLAND	Sirpa Nuotio <i>Jussi Pihlajamäki</i>	Seppo Ylä-Herttuala	Petri Mäkinen
FRANCE	Catherine Le Chalony <i>Simone Mergui</i>	Philippe Hantraye <i>Simone Mergui</i>	Emilie Hangen
ITALY	<i>Francesca Capone</i>	Franca Moretti <i>Francesca Capone</i>	Franca Moretti Chiara De Nuccio
LATVIA	Uldis Berkis	Liene Nikitina-Zake <i>Uldis Berkis</i> <i>Justine Krumina</i>	Zaiga Nora-Krukle
LUXEMBOURG	Jean-Claude Milmeister <i>Lynn Wenandy</i>	Frank Glod <i>Marine Duvivier</i>	Catherine Nannan
THE NETHERLANDS	Ana de Castro* (Chair) <i>Benien Vingerhoed-van Aken</i>	Saco de Visser* Alain van Gool* <i>Jan-Willem Boiten</i>	Andrea Mendez*
NORWAY	Olja Toljagic*	Janna Saarela	Anita Kavlie
PORTUGAL	Rui Santos Ivo <i>Carlos Alves</i>	Claudia Maria Coelho de Faria (Chair)	Helena Baião
SLOVAKIA	Ján Kočíšek Simona Foltinová	Erika Halasova	Jan Strnadel
SLOVENIA	Albin Kralj <i>Irena Mlinaric-Rascan</i>	Irena Mlinaric-Rascan	Dunja Urbanicic
SPAIN	Daniel Ruiz <i>Elena Domenech</i>	Laura Garcia Bermejo <i>David Velasco</i>	David Velasco
SWEDEN	Annika Jenmalm Jensen Helen Bergund*	Pontus Aspenström	Ulrika Bäckman

*Changed position in 2025
Alternate contacts (in italics)





Abbreviations

A	ACT-EU	Accelerating Clinical Trials in the European Union
	AI	Artificial Intelligence
	ATMP	Advanced Therapy Medicinal Products
B	BoG	Board of Governors
	BOND	Board of National Directors
C	CAR-T	Chimeric Antigen Receptor T-cell
	COST	European Cooperation in Science and Technology
D	DT	Digital Transformation
E	EASI-OMICS	Enabling Access to Services for Integrated OMICS
	EATG	European AIDS Treatment Group
	EATRIS	European Infrastructure for Translational Medicine
	EATRIS-ERIC	European Infrastructure for Translational Medicine – European Research Infrastructure Consortium
	EHDS	European Health Data Space
	EMA	European Medicines Agency
	EPF	European Patients’ Forum
	ERA4Health	European Partnership for Transforming Health and Care Systems
	ERIC Forum	European Research Infrastructure Consortium Forum
	ERDERA	European Rare Disease Ecosystem and Research Alliance
F	ESFRI	European Strategy Forum on Research Infrastructures
	EUCAIM	European Cancer Imaging Initiative
	FAIR	Findable, Accessible, Interoperable, Reusable
	FP10	Framework Programme 10
	GMP	Good Manufacturing Practice
	HLA	Human Leukocyte Antigen
	HTA	Health Technology Assessment
	ISIDORe	Integrated Services for Infectious Disease Outbreak Research
	iPSC	Induced Pluripotent Stem Cells
	NIH	National Institutes of Health
N	NIH	National Institutes of Health
	PERC	Patient Engagement Resource Centre
P	PEOF	Patient Engagement Open Forum
	SAB	Scientific Advisory Board
S	SAB	Scientific Advisory Board
V	VIIM	Vaccine, Inflammation and Immune Monitoring



View the full 'Glossary, abbreviations and acronyms' webpage here:
eatris.eu/glossary-abbreviations-and-acronyms





eatris

European infrastructure
for translational medicine

De Boelelaan 1117,
1081 HV Amsterdam,
The Netherlands
+ 31 (0)20 44 422 54
info@eatris.eu
www.eatris.eu

 bsky.app/profile/eatris.bsky.social
 linkedin.com/company/eatris-eric
 facebook.com/EATRIS.ERIC
 youtube.com/c/EATRIS-ERIC